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Abstract 
Retinitis Pigmentosa (RP) is a genetic condition that results in blindness. There are several hundred RP 
mutations associated with rhodopsin, a photosensitive GPCR pigment found within rod cells of the 
retina. Previous studies have shown that many rhodopsin RP mutants fold incorrectly or affect protein 
stability. This study investigates the effect of three RP mutants located in Extracellular loop 1 of bovine 
rhodopsin. Expression levels and protein folding have been examined using HEK 293 GnTI- cells and 
two methods have been used in an attempt to correct protein folding. The effects of these two 
correction methods on three mutations have been analysed by investigating their UV-visible 
absorption spectral properties, photobleaching properties, active light-activated state stability kinetics 
and pigment thermal stability. Pharmacological chaperone rescue with 9-cis-retinal was found to 
enhance expression levels and folding in two of the three mutant pigments. However, these rescued 
pigments were unstable at high temperatures (55 °C) when purified. The second approach involved 
the insertion of a disulphide bridge linking the N-terminal cap to ECL 3 and is known to increase the 
thermostability of WT rhodopsin. The N2C/D282C bond was found to repair two of the three mutant 
pigments and enhance stability, signal transduction, photobleaching and Meta-II stability to near WT 
levels. These two methods, when deployed together, had little additive effect. The main conclusion is 
that the N-terminal cap of rhodopsin is prevented from either folding correctly or docking correctly to 
ECL 3 due to the mutations located in ECL 1. However, when the N-terminal cap of rhodopsin is 
tethered in place by a disulphide bridge or when the retinal binding pocket is occupied, thermal 
stability and active state properties are restored in some rhodopsin RP mutants. 
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1. Introduction 
1.1- Anatomy of the Eye 
The eye is one of the most important organs of the human body, and vision is one of the most 
valuable senses that humans possess. Blindness is considered to be when an individual has visual field 
of less than 3/60 (perfect visual field is 20/20) and cannot read, write or manoeuvre as instructed to 
do so, whilst not having any other reason in which this may be the case (i.e. meaning they are not 
illiterate, dyslexic, dyspraxic or have any mobility issue restricting said individual from moving freely) 
(Genensky and Science, 1971, Thylefors et al., 1992). As of 2017, it has been reported that well over 
two million people in the UK are living with a form of blindness and over 360 million people worldwide 
(Bourne et al., 2017). With 19 million of those affected being children, and 1.4 million of those are 
irreversibly blind. As somewhat expected, 81% of all moderate to severe cases of visual impairment 
are attributed to those over the age of 50 years, this is most likely due to the ageing population 
(Bourne et al., 2017). This is expected to increase to 38.5 million by 2020 and then to over 115 million 
by 2050, according to a recent study (Flaxman et al., 2017). Some are born without the ability to see, 
whilst others lose it over time, yet 80% of all recorded visual impairment cases are either curable or 
preventable.  
The eye is composed of several different parts, some of which are shown in Figure 1.1. The cornea is 
the outermost covering layer of the eye. It is slightly dome shaped and protects all the inner eye 
structures from elemental damage (for example dust). Also, like skin, the cornea is made up of many 
layers. These layers can regenerate faster than other tissue types and help heal the eye (Bailey, 1987). 
Next, the sclera is the smooth white fibrous outer wall of the eye (the ‘whites’ of our eyes), but 
underneath is a pale brown layer with tendons that attach the eye to the eye socket. The sclera 
provides structural support for the eye but is flexible enough to allow the eye to move and see in a 
different direction to the position of the face and head (Kivelä et al., 1998). The pupil is the central 
black dot in the middle of the eye. It is actually a hole so that light can be focused onto the retina and 
objects can be clearly distinguished (Walsh and Charman, 1988). The iris is the pigmented area of the 
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eye surrounding the pupil (the part that determines what colour eyes someone has). The iris uses 
muscles to either dilate or contract the pupil depending on the amount of light that is present, 
allowing us to focus more easily.  
There are mucus excreting glands on the outside of the eye known as the conjunctiva glands, which 
help keep the eye moist/wet and prevent itching (Kobayashi and Kohshima, 2001). There are also 
lacrimal glands which are commonly known as the tear ducts. They too help keep the eye moist and 
remove particles of dust or dirt that could irritate the eye. The lens is located behind the pupil and is 
held in situ by the ciliary muscles. It is a clear layer that can change shape to focus light onto the retina 
(Delaye and Tardieu, 1983). The retina is composed of two photoreceptor cell types; rod cells and 
cone cells. These are layered across the back of the eye and transmit the light into electrochemical 
signals via the optic nerve. The back of the retina is called the macula and helps interpret the details of 
what is being viewed. The central region of the macula is the fovea, which heightens the resolution of 
the image sent to the brain (Kobayashi and Kohshima, 2001). The ciliary body muscles hold and 
control the eye lens movement. Whilst, the choroid resides between the retina and the sclera, 
providing a blood and nutrient supply to the eye via a capillary network (Kivelä et al., 1998).  
At the back of the eye, there is a gel which transports nutrients from the blood vessels to the internal 
eye structures called the vitreous humor. If debris becomes trapped in the vitreous humor then these 
appear as floaters in our vision (Bailey, 1987). The debris is caused by a condition known as posterior 
vitreous detachment (PVD), where the vitreous cavity shrinks and pulls away from the retina, resulting 
in debris being seen when stimulated. Once the vitreous cavity has become fully detached, the debris 
disappears. This is a very common condition affecting almost everyone over time, but rarely causes 
any problems (Sebag, 2004). The aqueous humor is the liquid that fills the front of eye and gives some 
form of structural support to the lens and cornea. It is separated into two chambers within the eye, 
the anterior and posterior chambers. The aqueous humor is drained through the Schlemm canal to 
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prevent any build-up of pressure, if this does not occur then glaucoma can develop (Kobayashi and 
Kohshima, 2001).   
 
Figure 1.1- Cross section of the eye. Labelled diagram of the eye, showing the relative position of the main structures both 
internal and external, from the cornea and pupil at the front to the optic nerve at the back. Adapted from Willoughby et al., 
2010. 
1.2- Rod and Cone Photoreceptor Cells 
There are two different types of photoreceptor cells within the eye; rod and cone cells. Cone 
photoreceptor cells are responsible for our colour vision and work optimally in bright light conditions. 
In humans there are three types of cone cells; S (small), M (medium) and L (long). Each type of cone 
cell responds to a different wavelength of light. S cone cells absorb short light wavelengths, peaking at 
420 nm (detects the colour purple). M cone cells absorb medium length light wavelengths, with a peak 
near 530 nm (detects the colour green). Finally, L cone cells respond to the longer wavelengths of 
light, peaking at 560 nm and allowing us to see the colour yellow. Using all three cone cells types in 
unison, we are able to visualise most colours of the visible light spectrum. Cone cells are 
approximately 40-50 µm long and 0.5-40 µm in diameter, with one end being slightly pointed or cone 
shaped (hence their name, see both Figures 1.2 and 1.3) and are mainly focused around the fovea. 
Cone cells can be separated into three sections; synaptic terminal, inner segment and outer segment. 
The synaptic terminal forms a synapse with a neuron from the optic nerve, the inner segment houses 
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all of the cell’s organelles (such as the nucleus and many mitochondria), whilst the outer segment 
contains the photopigment. The inner and outer segments are joined together by a connecting cilium 
(also known as primary cilium, and houses most of the protein molecules involved in the 
phototransduction cascade-see Figure 1.3) (Jin et al., 1994; Khanna, 2015). On the other hand, rod 
photoreceptor cells function in low light conditions and are responsible for night vision. Rod cells are 
more concentrated in the outer areas of the retina and less so near the macula. Rod cells are 
significantly longer than cone cells at 100 µm long and 2 µm in diameter. There are also far more rod 
cells than cone cells, with 100 million compared to 7 million, respectively. Rod cells are separated into 
the same three sections as the cone cells, but slightly differ in shape (Merino et al., 2011).  
 
 
 
 
 
 
 
 
 
Figure 1.2- Rod and Cone cell structure. Labelled diagram showing the overall shape of both types of photoreceptor cells 
along with the main sections and position of the nucleus.  
1.3- Retinitis Pigmentosa and Retinal Dystrophies 
Each one of the structures of the eye conveys a particular role, but each one also has the possibility to 
go wrong and cause a number of differing visual impairments or blindness. If the aqueous humor is 
not drained correctly then glaucoma can develop. Glaucoma is a condition where the optic nerve 
becomes damaged due to a build-up in pressure of the aqueous humor in the front of the eye 
(Quigley, 1996). In contrast, a breakdown of the choroid will lead to choroideremia. Choroideremia is 
an X-linked recessive disease which results in blindness because of mutations to the CHM gene 
encoding for Rab escort protein 1 (REP1). It currently has no cure and affects roughly one in 50,000 
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males worldwide (MacLaren et al., 2014). Choroideremia is a subtype of blindness referred to as 
retinal dystrophies. Retinal dystrophies are the most common form of blindness, aside from colour 
blindness. The two main types of retinal dystrophies are Age-related Macular Degeneration and 
Retinitis Pigmentosa (similar to choroideremia) (Gregory-Evans and Bhattacharya, 1998).  
Age-related Macular Degeneration (AMD) is a constant destruction of the central retinal region, 
known as the macula, resulting in the irreversible loss of central vision and leaving only peripheral 
vision, mainly for those who are aged 50 years or older (Klein et al., 2005). AMD has two different 
forms; wet and dry. Dry AMD is the slow degenerative onset and is caused by the deposition of 
metabolites (mainly lipofuscin) underneath the retinal pigment epithelium (drusen), whereas wet 
AMD has a quick onset caused by leaking blood vessels and can be treated with Lucentis or Avastin 
(Rosenfeld et al., 2006; Brown et al., 2019). Lucentis (or non-tradename Ranibizumab) is an antibody 
fragment used due to its anti-angiogenic properties (it prevents the growth of new blood vessels by 
targeting Vascular Endothelial Growth Factors, VEGF). Whereas Avastin (non-tradename Bevacizumab) 
is the ancestor antibody to Lucentis and is also used to treat various types of cancer (Fung et al., 2007, 
Avery et al., 2006).  
Retinitis Pigmentosa (RP) refers to a group of hereditary conditions affecting many genes and their 
subsequent proteins, very often via point mutations. One particular gene (RHO, chromosome position 
3q22.1) encodes for a protein called Rhodopsin and is located within the rod photoreceptor cells of 
the eye. The mutation (or sometimes mutations) will eventually lead to the death of the rod 
photoreceptor cells and cause the individual to turn blind (Campochiaro et al., 2017). The first stage of 
RP is night blindness (or nyctalopia), this is when rod photoreceptor cells in the eye have begun to die. 
Over time, large scale rod cell death will lead to the loss of peripheral vision and create tunnel vision, 
roughly by the time of adulthood. Finally, central vision will be lost as the remaining cone 
photoreceptor cells die (Hartong et al., 2006). Rod photoreceptor cells give us monochromatic vison, 
meaning they allow us to see in dim light conditions and most things appear to be black and white. 
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Whereas cone photoreceptor cells allow us to see in colour and detail. It is these different cells, and 
their corresponding pigments, that mediate our vision. There are three main types of RP: autosomal 
dominant Retinitis Pigmentosa, autosomal recessive Retinitis Pigmentosa and X-linked Retinitis 
Pigmentosa (Daiger et al., 2013). Autosomal dominant Retinitis Pigmentosa (adRP) is when a single 
faulty gene has been inherited from one parent, and this type of RP tends to be present throughout 
the family history (Sung et al., 1993). Autosomal recessive Retinitis Pigmentosa (arRP) is when two 
faulty genes have been inherited and the gene will be passed on to any offspring conceived. X-linked 
RP tends to only affect men and the faulty gene passed on is located on the X chromosome (Daiger et 
al., 2007) mainly the RPGR gene (Xp11.4) and the RP2 gene (Xp11.23) (Buraczynska et al., 1997; 
Sandberg et al., 2007). X-linked inheritance is when the mother has a faulty gene within one of her X 
chromosomes, resulting in her offspring having a 50% chance of inheriting it. This tends to affect 
males more than females as males only have one X chromosome, so will develop the condition if the X 
chromosome contains the faulty gene. For females, they can develop the condition if their father also 
has it, if not then they will become a carrier for the disease. This type of inheritance is also associated 
with Duchenne Muscular Dystrophy (DMD) and Haemophilia (Dobyns, 2006).  
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Figure 1.3- Phenotypical appearance of both healthy and RP affected retinal layers. Microscope image showing the 
phenotypic appearance of a healthy human retina (left) compared with a retina of a patient suffering from Retinitis 
Pigmentosa (RP) (right). In the centre is a diagram of the photoreceptor cells present within the retina. Far left shows a basic 
cross section of the eye and the different retinal layers (Hartong et al., 2006). 
 
1.4- Rhodopsin protein and Signal Transduction pathway 
Rhodopsin is a photosensitive G protein-coupled receptor (GPCR) located in the disc membranes of 
rod cell outer segments and is involved in the visual transduction pathway (sometimes referred to as 
the phototransduction cascade) (Chabre and Deterre, 1989). GPCRs are a superfamily of signal 
transduction proteins that can transmit communication signals across cellular membranes, rhodopsin 
is a Class A GPCR (defined as rhodopsin-like GPCRs based on function and sequence homology), there 
are six GPCR classes in total from A to F (Cherezov et al., 2007). The rhodopsin molecule consists of 
seven transmembrane α-helices connected together by three intracellular cytoplasmic loops (CL) and 
three extracellular loops (ECL) (Figure 1.4) (Sakmar, 2002). Along with this, rhodopsin can be divided 
into two distinctive parts; a protein called opsin and a derivative of Vitamin A known as 11-cis-
retinaldehyde (or 11-cis-retinal for short) (Palczewski et al., 2000). Both of these sections are 
covalently bound together. Retinal is the light sensitive molecule that mediates converting photons 
into a signal. Rhodopsin (or Rod Opsin, referring to opsins within the rod cells) is a type of vertebrate 
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visual opsin, which itself is a sub set of ciliary opsins (C-opsins), which are Type II opsins or animal 
opsins (Type I opsins are microbial opsins) (Shichida and Matsuyama, 2009, Feuda et al., 2012). 11-cis-
retinal, also called a chromophore, is bound by a Schiff base (covalent bond) to a lysine residue at 
position 296 in the seventh transmembrane helix (Zhukovsky et al., 1991). 11-cis-retinal, once bound, 
occupies the binding pocket of opsin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4- Three-dimensional ribbon diagram of rhodopsin and a two-dimensional model of bovine rhodopsin’s secondary 
structure showing the positions of most mutations from Class I-VII. Both show the seven α-helices along with connecting 
loops, as well as the carboxyl and amino terminals (Palczewski et al., 2000, Athanasiou et al., 2017).  
 
When a photon of light is absorbed by the rhodopsin pigment within the rod cell, a change in shape 
occurs. In dark conditions the retinal exists in the 11-cis-retinal state, but exposure to light stimulates 
a conformational change to the all-trans retinal state (it is now referred to a Metarhodopsin II - Meta 
II). This conformational change causes an increased affinity for a regulatory protein called transducin 
(a G protein) (Chabre and Deterre, 1989). Once transducin has bound to the Meta-II molecule (R*G in 
Figure 1.5), the alpha G protein subunit exchanges Guanosine Diphosphate (GDP) with Guanosine 
Triphosphate (GTP). This in turn causes the G protein alpha subunit to dissociate from the G protein 
C 
N 
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beta and gamma subunits, activating the molecule. The now free alpha subunit (G*) binds to a cyclic 
Guanosine Monophosphate (cGMP) phosphodiesterase effector protein and an inhibitory gamma 
phosphodiesterase molecule (γ PDE), to prevent the G protein beta and gamma subunits from being 
blocked and inactivated. This then activates the cGMP phosphodiesterase and converts cGMP to 5’-
GMP, via hydrolysis. The reduction in cGMP concentration causes cGMP regulated sodium and calcium 
ion channels to close, changing the rod cell from a depolarised to a hyperpolarised state, by changing 
the cell’s potential. In the hyperpolarised state, the glutamate neurotransmitter is not released into 
the synaptic cleft for recognition by ganglion and bipolar cells. This is the visual transduction pathway 
or the phototransduction cascade in Figure 1.5 (Rosenbaum et al., 2009).  
 
 
 
 
 
 
Figure 1.5- Simplified diagram of the phototransduction signal pathway. Main stages of the phototransduction pathway, 
from the absorbance of a photon to the activation of Transducin to hyperpolarisation of the rod cell. R is rhodopsin, G is 
transducin, R+ is Meta II, GC is guanylyl cyclase (Leskov et al., 2000).  
Once this pathway has terminated, the rod cell must return to a resting depolarised state, and 
rhodopsin must be deactivated. A protein called rhodopsin kinase (RK) phosphorylates several serine 
residues in the cytosolic tail region, inhibiting the transducin binding. At the same time, arrestin (a G 
protein-coupled receptor regulatory molecule) binds to the phosphorylated rhodopsin molecule. As 
the activity of the rhodopsin molecule reduces, an RGS protein (regulator of G protein signalling) 
reverts the transducin bound GTP back to GDP, deactivating the G protein. Whilst cGMP 
concentrations return to normal, so does the calcium ion influx. As calcium ion concentrations 
decrease, guanylyl cyclase enzymes become activated and replenishes the cGMP stocks. Altogether, 
this causes the rod cell to become depolarised again (Muradov and Artemyev, 2000).  
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The activation and deactivation pathways of rhodopsin (or rod cells) only occur in low light conditions. 
During the day, when rod cells are exposed to excessive amounts of light, they become desensitised. 
As the rhodopsin molecules are phosphorylated by RK, arrestin becomes bound. Arrestin limits the 
interactions between transducin and Meta-II, as well as helping clathrin dependent endocytosis 
machinery to begin receptor mediated endocytosis (Okawa and Sampath, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1.6- Rhodopsin activation and deactivation cycle. Flow chart displaying each step of the cycle from the inactivated 
stable-state Rhodopsin to the Meta-II activated state, along with retinal state change and reformation (Leskov et al., 2000).  
 
To regenerate 11-cis-retinal, all-trans retinal binds with NADH to form all-trans retinol. All-trans retinol 
combines with a fatty acid and forms all-trans retinyl ester (Moiseyev et al., 2005). This retinyl ester 
can bind with water and NAD+ to reform 11-cis-retinal (Jin et al., 2007). The regeneration cycle is 
shown in more detail in Figure 1.7.  
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Figure 1.7- Enzymatic pathway showing the visual cycle of retinal. 11-cis-retinal is converted to all-trans retinal following 
the activation of bound rhodopsin by exposure to light in the ROS. All-trans retinal is the converted back to 11-cis-retinal in 
the retinal pigment epithelium by binding to NADH to form all-trans retinol, a fatty acid to form all-trans retinyl ester and 
water to regenerate 11-cis-retinal (Moiseyev et al., 2005). 
 
1.5- Rhodopsin Mutation Classes 
Along with the different types of RP there are seven different classes of mutations to the rhodopsin 
protein, each of which has its own characteristics. Class I mutations are when the mutant rhodopsin 
protein folds correctly or normally but is not transported out of the Endoplasmic Reticulum (ER) and 
Golgi apparatus, to the outer segments of the rod cell. Class II mutations involve misfolded proteins 
that are unable to leave the ER and Golgi to be transported to the cell outer segments. Class III 
mutations interfere with endocytosis and class IV mutations affect rhodopsin stability and post 
translational modifications (PTM), but do not tend to influence protein folding as such. Class V 
mutations show an increased amount of transducin activation (Mendes et al., 2005). And finally, class 
VI and VII mutations refer to constitutive activation (mutated protein causes constant activation) and 
dimerization deficiency (remain as monomers and unable to form quaternary protein structures), 
respectively (Athanasiou et al., 2017; Ploier et al., 2016). 
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Table 1.1- Classifications of rhodopsin mutations. Describes the basic characteristics of each of the seven mutations classes 
along with whether the mutant protein formed is misfolded and some examples.  
Mutation Class Characteristics  Mutation examples Misfolded 
Class I Normal folding, not 
transported to outer 
segments 
T342M, P347S No 
Class II Misfolded, contained 
within ER 
P23H, G106R, K296E Yes 
Class III Affects endocytosis R135G No 
Class IV Affects stability and 
PTM 
T4K Not always 
Class V Increased activation of 
transducin 
M44T, V137M No 
Class VI Constitutive activation T94I, A295V No 
Class VII Dimerisation 
deficiency 
F45L, F220C No 
 
Therefore, theoretically, every rhodopsin mutation can be categorised into one or possibly more than 
one of the classes above. However, this is incredibly difficult to prove as there are over 150 distinct 
rhodopsin mutations that have been clinically diagnosed for adRP alone, and it is likely that some 
mutations remain either unclassified or undiscovered (Reeves et al., 2002). Yet some of these 
mutations seem to occur more frequently than others. The most common rhodopsin mutation is 
P23H, this is where the amino acid Proline has been replaced by the amino acid Histidine at residue 
number 23 (refer to Figure 1.4). P23H is a missense mutation that causes a mild adRP phenotype in 
patients, as well as having the characteristics of both class II and class IV mutations (it both prevents 
protein movement from the ER and affects overall stability) (Tam et al., 2010). Similarly, T17M 
(Threonine is replaced by Methionine at residue 17) is another common missense mutation but does 
not result in such a severe adRP phenotype. Other common rhodopsin mutations include; Q64ter, 
G106R, A269G, and P347S. Q64ter is where Glutamine has been replaced by a stop codon/termination 
sequence at residue 64, giving a nonsense mutation. Although this mutation is currently unclassified, it 
has been shown to cause advanced retinal degradation (John et al., 2000). G106R, Glycine to Arginine 
at residue 106, is a well-studied common class II mutation that also causes advanced degradation of 
the retina. P347S, Proline to Serine at residue 347, is a well-studied class I mutation despite being less 
common than the previously mentioned two. Being a class I mutation the protein formed does not 
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reach the outer cell segments, so increasing the concentration of the retinal chromophore available 
has virtually zero effect (Li et al., 1998). In a slightly different aspect A269G, where Alanine is 
substituted by Glycine at residue 269, is a polymorphism. A polymorphism is a Mendelian trait that is 
present in the wild population of a species in a minimum of two individuals (both phenotypically and 
genotypically) with an occurrence frequency more than 2% (Meyer and Genomics, 1991). This 
particular polymorphism results in a phenotypically silent mutation as the DNA and protein code have 
been altered, but the individual with the mutation does not exhibit RP to any degree (Sung et al., 
1991).  
1.6- Potential Treatments and Therapies 
Over the years vast amounts of research have been undertaken to try and understand RP, albeit to no 
avail as of yet. However, there are some techniques that do have the potential to one day be 
developed into a treatment and/or a cure. The four main categories of treatments for RP are; gene 
therapy, cell transplantation, neurological-retinal prosthetics and pharmacologic therapeutics 
(Shintani et al., 2009).  
Gene therapy refers to altering or correcting the current genetic sequence, potentially by inserting a 
site-specific mutation or by inserting a transgene with the aid of a virus. Gene augmentation therapy 
using adenovirus-associated 2/5 vector human RPGR gene along with GRK1 promoters, injected into 
the retina, has shown some positive results for X-linked RP, but not so much for adRP (Beltran et al., 
2012). The findings of this investigation showed that the therapy must influence both photoreceptor 
cell types, due to the shared protomer region for the opsins (Beltran et al., 2012). This technique is 
very popular as many other studies also insert a human transgene to mitigate rod cell degeneration 
(Cideciyan et al., 2018). An alternative to inserting a gene would be to create a site-specific mutation 
which corrects the faulty genetic code. A way to achieve this is to use CRISPR/Cas9. Clustered 
Regularly Interspaced Short Palindromic Repeats with Caspase 9 is a bacterial immune response in 
order to protect its genetic integrity and was discovered by the Japanese molecular biologist 
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Yoshizumi Ishino in 1987 from Escherichia coli (Zakeri et al., 2012). CRISPR/Cas9 works by creating 
multiple small targeted sequences in DNA, where the genetic code can alter a genes function, either 
by knocking out (reducing the gene function to zero) or knocking in (increasing or altering gene 
function) (Housden and Perrimon, 2016).  
 
Cell transplantation involves the insertion of stem cells into the retina in order to alleviate the 
symptoms of RP by the ‘donated’ cells introducing the correct genetic sequence or protein. The most 
logical form of this would be to use induced pluripotent stem cells (iPSCs). However, the autologous 
cells would need to be repaired using a technique like CRISPR/Cas9 as the patient’s cells would still 
contain the mutations (Bassuk et al., 2016). This means that human embryonic stem cells (hESCs) or 
allogenic cells from a donor may be a more suitable option. The hESCs will contain the correct genetic 
sequence and will not have a risk of being rejected by the recipient, the allotransplanted cells 
(compatible cells from a genetically different individual of the same species) may be rejected. The cells 
would be surgically implanted into the macular region of the retina and monitored over several years 
to observe any improvements in eyesight or RP progression (Kaplan et al., 1997). But most of these 
studies have proved either unsuccessful or inconclusive.  
 
Along with cell transplants, there have also been prosthetic retinal implants. An example of this is the 
surgical insertion of a Retina Implant Alpha AMS, a device which sits on the retina and stimulates the 
inner retina to respond normally to incoming light. Essentially, restoring an individual’s sight to normal 
without interfering with the rhodopsin gene (Edwards et al., 2018). Or an artificial silicon retina 
microchip could be implanted into the same region to give a similar effect (Chow et al., 2004). Studies 
like this, such as the Argus® II Retinal Prosthesis System, have shown some improvement to the visual 
fields of some individuals, but the rates of success are far from being significant. The Argus II system is 
made up of a 200 µm 60-electrode microarray (implanted onto the back of the retina and optic nerve) 
connected via a coiled link to an external video processing unit (VPU) and a miniature camera attached 
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to a pair of glasses. The cameras work in real time and transmit the images as stimulating pulses to the 
optic nerve, which can then be interpreted by the brain in the same way as viewing something 
normally. In essence, the idea is for the cameras to take over the role of the eyes and allow the 
individual to ‘see’ via an unconventional route (Ahuja et al., 2011). 27 subjects were used for this 
study, so more investigations are needed to confirm whether this system is accurate, reliable and 
should be used more widely. But of these 27 subjects, 26 showed a significant improvement in 
identifying a given point and touching it when using the system compared to without (Ahuja et al., 
2011). 
 
 
 
 
Figure 1.8- Argus® II Retinal Prosthesis System. Illustrations showing the position of the electrode implant (left), external 
video processing unit-VPU (centre) and cameras mounted to a pair of glasses (right) (Ahuja et al., 2011).  
Pharmacological treatments involve using small molecules, such as retinal, to alter the mutant 
rhodopsin pigment instead of interfering with its genetic sequence. Pharmacological chaperones do 
this by acting as scaffolding proteins and allow the misfolded proteins to reach their native 
conformation (Morello et al., 2000). These small molecules can be used to stabilise the mutant 
rhodopsin pigment and help stop the progression of RP (Chen et al., 2018). This is one of the main 
focuses of this project and will be discussed later.  
1.7- Techniques and Rationale 
The focus of this project is to investigate what effect three particular rhodopsin mutations have and 
infer this onto the mechanism that RP seems to follow, as well as its severity. Alongside this, a 
secondary background mutation will also be investigated to see whether this has any mitigating rescue 
properties when present with the other primary mutations (meaning does the secondary mutation 
help ‘fix’ the rhodopsin molecule). Objectives that will also be looked at include: what role the 
22 
 
chromophore has and whether changing this can yield any beneficial results and the effect of mutating 
the docking region for the cap.  
The three mutations that will be investigated are G101V, V104F and G106W. For the mutation at 
residue 101 Glycine has been replaced by Valine, for residue 104 Valine is substituted by 
Phenylalanine and at residue 106 Tryptophan replaces Glycine (Figure 1.9). Each of these mutations 
has been created within separate bovine rhodopsin genes and DNA extracted. Along with these 
mutants, there is also a bovine wild type rhodopsin for comparison at each stage (please note, bovine 
rhodopsin has a slightly different genetic code to human rhodopsin, resulting in a different order of 
amino acids-see Appendix). Very few studies have been conducted on the G101V and V104F 
mutations, but some similar mutations have been investigated. One study has shown that at residue 
104, Valine has been replaced by Isoleucine. The result of this study was that this residual substitution 
did not result in a RP phenotype, meaning that the mutation has a phenotypically silent effect, 
therefore V104F may have the same effect (Macke et al., 1993).  Whereas the G106W mutation has 
been investigated to some extent and is believed to interfere with the Schiff base (overall protein 
folding, stability and chromophore association as well), preventing the formation of the rhodopsin 
molecule, but does not reduce the levels to zero (Kaushal and Khorana, 1994). All of these mutations 
are located on Extracellular loop 1 (ECL 1) and are either Class II mutations (G106W) or unclassified 
(Figure 1.4).  
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Figure 1.9- PyMol images of the mutations G101V, V104F and G106W. PyMol diagrams showing the original residue at their 
corresponding base locations with their mutated versions to the right. A) Highlighted in red is Glycine at position 101 with the 
mutated Valine next to it, B) Highlighted in green at position 104 are Valine and Phenylalanine, C) Highlighted in dark blue are 
Glycine and Tryptophan at position 106. 11-cis-retinal is shown in yellow bound to Lysine 296 (K296). 
 
The secondary background mutation will replace Asparagine and Aspartic Acid with Cysteine at 
residues 2 and 282, respectively (N2C/D282C). This mutation results in a disulphide bridge  
forming between the two new cysteine residues, giving the intracellular N-terminus and ECL 3 a more 
stable configuration. The disulphide bridge replaces the weaker hydrogen bond between the two 
previous amino acids (Asparagine and Aspartic Acid) (Standfuss et al., 2007). The replacement of 
A 
B 
C 
G101 
G101V 
V104 V104F 
G106 
G106W 
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Asparagine with Cysteine also results in the removal of a glycosylation site at residue 2, leading to a 
reduction in protein size (shown in Figure 3.9, Reeves et al., 2002). 
 
 
 
 
 
 
 
 
 
 
Figure 1.10- Secondary structure of the N-terminal cap for rhodopsin. Showing where the disulphide bridge (indicated by 
the dotted lines) will form between inserted cysteine residues (in yellow) at positions 2 and 282 (Opefi et al., 2013).   
Some preliminary results have shown that the presence of this background mutation (N2C/D282C), 
whether other mutations are present or not, does increase the thermostability of rhodopsin (Deupi et 
al., 2012; Opefi et al., 2013).  
 
Figure 1.11- Skeletal diagrams of the main seven amino acids involved in the rhodopsin mutations in this project, along 
with their appropriate functional groups.  Diagrams start with the most basic amino acid Glycine and become more complex 
through to Tryptophan. The structure of each can be used to theorise any additional (or reduced) interaction when one 
amino acid is replaced by another at positions 101, 104 and 106 in the rhodopsin protein.  
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This project will also include investigating pharmacological chaperone rescue. As stated earlier, this 
involves using small molecules to bind and stabilise the rhodopsin structure rather than changing its 
genetic code. A simple way to do this is to use the natural ligand retinal itself. 11-cis-retinal is the 
natural derivative but it can be replaced by 9-cis-retinal, a variant that is believed to have some rescue 
properties (the term cis refers to the functional groups being on the same side of the carbon chain 
whilst trans means on opposite sides). This is because 9-cis-retinal has a very similar structure to 11-
cis-retinal, meaning that it behaves in an almost identical way. The main difference, apart from 
structure, is that 9-cis-retinal exists in a slightly higher energy state, giving it the potential to increase 
stability when bound to a mutated rhodopsin molecule (Sekharan and Morokuma, 2011) and 9-cis-
retinal is readily available.  
Figure 1.12- 11-cis-retinal and 9-cis-retinal skeletal diagrams. Diagrams showing the two different version of natural retinal.  
 
A breakdown of the techniques that will be used in this project are: bacterial transformations, gel 
electrophoresis (agarose and SDS-PAGE), cell tissue culture, calcium chloride transfections, 
pharmacological chaperone rescue with 9-cis-retinal, disulphide bridge mediated repair, 
immunoaffinity purification, UV-visible absorbance spectroscopy, Metarhodopsin-II decays and 
thermal decays. At least three repeats of each data set will be carried out to gain concordant results 
and exclude any outliers. All of these techniques will be explained in more detail in the methodology 
chapter.   
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The cells being used are HEK 293 GnTI- cells (Human embryonic kidney) (n-acetylglucosaminyl 
transferase I knockout). HEK 293 cells are an extensively used cell line of epithelial origin that was first 
established by transformation with sheared Adenovirus type 5 DNA in 1973 by Alex van der Eb and 
Frank Graham (Graham et al., 1977). This transfection with adenovirus DNA allows the cells to grow 
and be cultured with a much higher efficiency, but the DNA had to be sheared (made to correct 
fragment size) in order to prevent the HEK cells from lysing (Graham et al., 1978). The reasons that 
this particular cell line is being used are because they are ideal for expressing transgenes from both 
mammalian and non-mammalian sources and are especially good for the study and isolation of 
particular receptor channels (Thomas et al., 2005). GnTI is a type II protein located in the Golgi 
apparatus membrane and, because of its name, it has an important role in the initiation of complex N-
glycan formation in both plants and animals (Burke et al., 1994, Schoberer et al., 2009). These N-
glycans (complex carbohydrates bound to Asparagine resides via glycosidic bonds) are essential at 
particular sites and are believed to have some role in aiding stabilise the tertiary and quaternary 
structures of rhodopsin (Reeves et al., 2002; Stanley et al., 2017). Although HEK cells can function 
without GnTI present (termed GnTI-), the formation of complex N-glycans can be interrupted.  
1.8- Investigative Aims and Hypotheses 
The main hypotheses are:  
• The use of either disulphide bridge mediated repair or pharmacological chaperone rescue will 
result in a more stable mutant rhodopsin protein being formed, when compared to its non-
repaired or non-rescued counterpart.  
• The use of both rescue and repair methods together will result in an added stability effect in 
comparison to each method being used individually.  
The overall hypothesis for this project is: The rhodopsin RP mutations G101V, V104F and G106W alter 
ECL 1 structure which prevents the N-terminal cap either from folding correctly or from docking to ECL 
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3. But the use of pharmacological chaperone rescue and/or disulphide bridge mediated repair restores 
native rhodopsin function and stability.  
The findings of this project may have much larger implications than just research, they may develop 
into ideas for a treatment for RP. If the stated hypotheses are proved correct, then initiating a 
disulphide bridge (not practical to carry out in humans at the moment) or supplementing 11-cis-retinal 
with 9-cis-retinal could prevent the progression of rod cell death and possibly stop RP. But other 
techniques like CRISPR/Cas9 or stem cell transplants could yield better results, be safer for the 
individual and are far better understood.  
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2. Methodology and Materials 
Chemicals/Reagents Provider Reference number 
9-cis-Retinal  Sigma R5754 
Agar Granules Melford Biolaboratories Ltd GM1002 
Agarose-gel Ladder Sequence Thermo Scientific SM0313 
Ammonium Phosphate (APS) Melford Biolaboratories Ltd A1512 
Bes  Sigma B6420 
Bis-acrylamide  Sigma A3574 
Bis-Tris Propane (BTP) Melford Biolaboratories Ltd 64431 
Calcium Chloride (CaCl2)  Sigma C5670 
Dimethyl Sulphoxide (DMSO) Sigma  67685 
Disodium Phosphate (Na2HPO4) Sigma 71643 
DMEM and F12 (Dulbecco’s Modified Eagle 
Medium) 
Lonza, Bio-Whittaker BE12-719D 
FastDigest Green Buffer (10x) Thermo Scientific  B72 
Gel Red Nucleic Acid Stain in water 
(10,000x) 
Sigma SCT123 
Glycerol Fisher Chemical G0650 
Glycine  Fisher Chemical G0800 
Heat-Inactive Foetal Bovine Serum Thermo Scientific (HyClone) SV30180.03 
Hydrochloric Acid (HCl) Sigma 7647 
L-Glutamine Lonza, Bio-Whittaker BE17-605F 
Monopotassium Phosphate (KH2PO4) Melford Biolaboratories Ltd P0574 
n-Dodecyl β-D-maltoside (DDM) Sigma D4641 
PenStrep (Penicillin-Streptomycin) Lonza, Bio-Whittaker DE17-602E 
pMT4 plasmid Massachusetts Institute of 
Technology (Franke et al., 1988) 
N/A 
Potassium Chloride (KCl) Sigma P9541 
Skim powdered Milk Marvel N/A 
Sodium Azide (NaN3) Sigma S8032 
Sodium Chloride (NaCl) Fisher Chemical S3160 
Sodium Dodecyl Sulphate (SDS) Melford Biolaboratories Ltd B2008 
Sodium Hydroxide (NaOH, pellets) Fisher Chemical 54920 
Tetramethylethylenediamine (TEMED) Melford Biolaboratories Ltd T3100 
Triton X-100 Sigma T9284 
Trizma base  Sigma T1503 
Trypsin Lonza, Bio-Whittaker BE02-007E 
Tryptone Melford Biolaboratories Ltd T1332 
Tween 20 Melford Biolaboratories Ltd P1362 
Yeast Extract Powder Melford Biolaboratories Ltd  Y1333 
 
Equipment 
Heraeus Multifuge 3 S-R Centrifuge  
Hoefer PS600 600-volt Power Supply (with Bio-Rad Centurion range) 
Marshall Scientific Eppendorf 5417R Centrifuge 
New Brunswick Scientific Innova 43 & 4300 Incubated floor Shakers 
Perkin-Elmer Lambda 35 UV-vis Spectrophotometer 
Perkin-Elmer LS 50B Fluorometer  
Schott KL 1500 compact light source 
Sorvall Discovery 90SE Ultra-Centrifuge 
Thermo Scientific Nanodrop (ND) 1000 Spectrophotometer 
Vilber Fusion FX Fluorescence Imager 
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Buffer Reagents 
2x YT Broth (2x YT with Agar)-1 L 5 g NaCl, 10 g Yeast Extract, 16 g Tryptone (3 g 
Agar per 200 ml Duran bottle) in MilliQ water 
2x Bes Buffer- 100 ml 50 mM Bes, 250 mM NaCl, 1.5 mM NaHPO4 [pH 
7.02] with NaOH, in MilliQ water 
10x CaCl2 2.5 M CaCl2 dissolved in 100 ml distilled water 
4x Running Gel Buffer 18.15 g Tris-HCl [pH 8.8] in 100 ml of MilliQ 
water 
4x Stacking Gel Buffer 3 g Tris-HCl [pH 6.8] in 50 ml of MilliQ water 
H2O saturated Iso-butanol 10 ml Iso-butanol mixed with 3 ml H2O 
10x Tank Buffer- 500 ml 15.14 g Tris, 72.07 g Glycine, 5 g SDS, dissolved 
in MilliQ water 
1x Tank Buffer 100 ml of 10x Tank buffer and 900 ml MQ H2O 
1x Transfer Buffer 100 ml 10x Tank buffer, 200 ml Methanol, 
made up to 1 L with MQ H2O 
4x Loading Buffer 0.125M Tris-HCl [pH 6.8], 4% SDS, 20% Glycerol, 
0.2 M DTT, 0.02% Bromophenol Blue 
10x PBS (Phosphate Buffered-Saline)- 800ml  64.05 g NaCl, 1.61 g KCl, 1.63 g KH2PO4, 11.39 g 
Na2PO4.2H2O, dissolve in water and autoclave 
Blocking Buffer 5 g Skim powdered milk, 50 µl Tween 20, few 
grains of NaN3, made up in 50 ml 1x PBS 
Wash Buffer 2.75 g Skim powdered milk, 550 µl Triton X-100, 
made up in 550 ml of 1x PBS 
Freezing Media Buffer  10% sterile HybriMax DMSO (WARNING: 
double glove and avoid all contact to the skin) 
and 90% DMEM-F12 media 
Solution 1- 100 ml 5 ml 1 M Tris (pH 7.6), 2 ml 0.5 M EDTA and 
autoclaved. 100 µl 100 mg/ml Heat-treated 
RNAse and stored at 4 ˚C 
Solution 2- 10 ml 200 µl 10 M NaOH, 1 ml 1% SDS, 8.8 ml H2O 
Solution 3- 100 ml  38.2 g 4 M Guanidine Hydrochloride, 4.9 g  
0.5 M Potassium Acetate, pH to 4.2 with Glacial 
Acetic acid with stirring at 70 ˚C before 
autoclaving 
Binding Buffer- 200 ml  95.53 g 5 M Guanidine Hydrochloride, 0.48 g 
Tris in 124 ml MQ water, autoclave, add 76 ml 
ethanol 
Wash 1- 200 ml 2.34 g NaCl, 4 ml 1 M Tris (pH 7.5), 10 ml 1 M 
EDTA in 84 ml water (pH with Glacial Acetic 
acid, stirring, 70 ˚C) and autoclave. Add 116 ml 
ethanol 
Wash 2- 100 ml 20 ml sterile MQ water and 80 ml ethanol 
BTP (High-salt BTP)- 100 ml 2.82 g BTP to make 100 mM stock (with  
140 mM NaCl, 0.82 g) 
All medias and buffers listed above were mixed together in a beaker (size dependent upon the volume 
of the end solution) using a magnetic stirring flea (on a Fisher-Scientific Mixer) to ensure all reagents 
dissolved. Following this, the pH of the buffers were adjusted (if needed) with the stated chemicals 
and poured into appropriately sized Duran bottles and autoclaved (again, if needed).  
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2.1 General Methods 
2.1.1 Preparation of growth media 
2x YT Broth (200 ml, 20 x 10 ml universal tubes)- 1 g NaCl, 2 g Yeast extract, 3.2 g Tryptone.  
The 200 ml solution was aliquoted into 10 ml amounts using a pipette aid and a 25 ml pipette.  
Overnight culture broth (800 ml 2x YT, 100 ml x 8 L conical flasks)- 12.8 g Tryptone, 8 g Yeast extract,  
4 g NaCl.  
800 ml was made in total with 100 ml used per conical flask.  
2.1.2 Culturing techniques 
Ampicillin growth plate- Agar solution, 200 µl Ampicillin. 
The agar was melted in a microwave to a point of a rolling boil and was then allowed to cool to a 
touchable temperature (approximately 50 ˚C). 200 µl of ampicillin (concentration 100 mg/ml, 1:1000 
dilution) was then added and gently mixed in to the 200 ml of 2x YT broth. The broth was poured 
equally into eight sterile petri dishes near a lit Bunsen flame, once set the plates were inverted to 
prevent condensation build-up.  
Transformation- Escherichia coli XL1 blue  
1 µl of each rhodopsin RP mutant glycerol stock was diluted with 9 µl of MilliQ water in Eppendorf 
tubes and chilled on ice. 1 µl of diluted sample was added to 40 µl of competent E. coli cells and 
cooled on ice for 30 minutes, before being heat shocked in a water bath at 42 ˚C for 45 seconds and 
returned to ice for a further five minutes. 500 µl of 2x YT broth was added before the tubes were 
placed on a shaker (250 rpm, 37 ˚C, 10 minutes). 50 µl of each sample was added to the appropriate 
growth plate and incubated at 37 ˚C for roughly 16 hours.  
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Day Culture- 3 ml 2x YT broth, 25 µl Ampicillin. 
A single colony was picked using a sterile toothpick and gently dipped into 3 ml of broth solution with 
3 µl of ampicillin in a 15 ml centrifuge tube, one tube for each mutant sample. The tubes were then 
placed onto a holding rack and incubated overnight on a shaking incubator (37 ˚C, 250 rpm).  
Glycerol mutant stocks 
500 µl of each mutant sample (from original ampicillin growth plates) was added to 500 µl of 50% 
glycerol and stored at -80 ˚C in cryopreserve tubes. 
Streak plates 
A pipette tip was used to apply glycerol stock sample to the ampicillin plate. Sterile toothpicks were 
used to streak the sample around the plate and isolate colony growth and incubated overnight at  
37 ˚C.  
Overnight culture 
A 100 µl amount of day culture was added to conical flasks (100 ml of 2x YT broth) with 100 µl of 
Ampicillin. Incubated overnight at 37 ˚C, 200 rpm on an Innova 43 or 4300 floor incubator. Samples 
were removed the following morning and centrifuged in 50 ml centrifuge tubes (4500 rpm, 10 
minutes) and the pellets frozen at -20 ˚C for MidiPrep. 
2.2 Molecular Biology Methods 
2.2.1 Sample Sequencing 
Samples from agarose gel were sent to Eurofins for standard Sanger sequencing. Samples were diluted 
to 100 ng/µl in a volume of 15 µl. Both F1 and F2 primers were diluted to 10 pmol/µl in a volume of  
55 µl. Each sample and primer was placed into a separate Eppendorf tube and sent for sequencing. 
Sample numbers were recorded and used to label sequencing results received three days later.  
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2.2.2 Agarose Gel Electrophoresis  
Agarose gel (Midi gel, 20 wells)- 1.2 g Agarose, 1x TAE buffer, DNA ladder solution, mutant samples, 
restriction endonucleases NotI and EcoRI 
1.2 g of Agarose was dissolved in 150 ml of 1x TAE buffer and heated to a boil before being allowed to 
cool. The gel mixture was then poured into the gel casing (assembled as per instructions) with well 
comb and left to set (30 minutes). Once set, the gel was placed into the gel tank and covered in 1x TAE 
buffer. 5 µl (0.1 µg) of ladder sequence, 10 µl 1x loading buffer and 5 µl gel red added to well number 
one, the following wells contained alternating undigested (2 µl mutant sample, 2 µl 10x Fast Digest 
Green buffer, 5 µl Gel red and 11 µl MilliQ water) and double digested (1 µl of both restriction 
enzymes, 2 µl mutant sample, 2 µl 10x Fast Digest Green buffer, 5 µl Gel red and 9 µl MilliQ water) 
samples. The midi gel was run for 75 minutes at 100 V, visualised and photographed using a UV 
transilluminator (302-312 nm).  
2.2.3 DNA Extraction  
Miniature DNA Preparation- MiniPrep 
1 ml of day culture broth was centrifuged (two minutes, 20 ˚C, 14000 rpm) and the supernatant was 
removed. The pellet was resuspended in 250 µl resuspension solution and vortexed to mix. 250 µl of 
lysis solution was added and inverted five times, followed by 350 µl of neutralisation solution and 
inverted five times. The next step was centrifuging (five minutes, 20 ˚C, 14000 rpm) and the 
supernatant was transferred to a GeneJet column and centrifuged (one minute). 500 µl of wash 
solution was added, centrifuged and the flow through discarded (repeated twice). This was followed 
by another centrifugation (one minute) to remove any excess wash solution and ethanol. The GeneJet 
column was then transferred to an Eppendorf tube and 50 µl of MilliQ water (preheated to 65 ˚C) was 
added before being centrifuged for two minutes. The purified plasmids were then stored at -20 ˚C.  
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Medium scale DNA Preparation- MidiPrep (Kit) 
The pelleted E. coli cells from the overnight culture were resuspended in 5 ml of SN1 solution and 
vortexed until no clumps were left. Next the cells were lysed with 5 ml of SN2 and inverted to mix. 
Following this, 5 ml of SN3 was used to neutralise the solution once inverted several times until there 
was no blue colour visible (only an off-white flocculate). The lysate was then transferred to a 
Nucleospin Plasmid Filter column and centrifuged for two minutes at 3700 rpm. Afterwards, the 
column was discarded and roughly 7 ml of SN4 was added to the filtered solution (approximately half 
the volume of the filtered solution), vortexed to mix for five seconds. The DNA solution was then 
filtered using a NucleoSnap Plasmid column on a vacuum manifold, set to -0.3 bar. The column filter 
was then washed with 2 ml of SN5 and then 4 ml SN6. Following on, the funnel was broken away from 
the spin column, which was placed into a collection tube and centrifuged at 1000 rpm for one minute. 
The column was then transferred to an Eppendorf tube and 500 µl of MilliQ water was added 
(preheated to 65 ˚C). This was again centrifuged and then frozen at -20 ˚C. All steps listed above are 
carried out for each individual pellet.  
Medium scale plasmid DNA Preparation- MidiPrep (Celite) 
The pelleted E. coli cells from the overnight culture were resuspended in 5 ml of Solution 1 and 
vortexed until no clumps were left. Following this, 5 ml of Solution 2 was added, and the tubes 
inverted several times to mix the solutions for less than four minutes. 5 ml of Solution 3 (on ice) was 
added before being mixed via inversions. The tubes were then centrifuged for 30 minutes, 4000 rpm 
at 4 ˚C (but room temperature is acceptable if there is no alternative). After the centrifugation, the 
supernatant was poured through a tea bag into a separate 50 ml tube and the flocculate discarded (a 
new glove is advised for each sample to avoid cross contamination of the plasmids). The plasmid 
solution was then added to 0.4 g of Celite in 10 ml Binding buffer and mixed by rotation for 10 
minutes. The 25 ml solution was then poured into a 5 ml Pierce column with funnel extender and 
allowed to pack under pressure on a vacuum manifold. Once the solution had run through, 10 ml of 
Wash 1 followed by 3 ml of Wash 2 were added and run through. The resin was left on the manifold 
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until it turned white in colour and the column no longer felt cold. However to save water, the column 
was centrifuged at 4000 rpm for 5 minutes after both washes before being returning to the manifold. 
The DNA was eluted out using two separate additions of 500 µl of 65 ˚C MQ water and centrifuged for 
10 minutes at 4000 rpm. The DNA can then be measured and stored at -20 ˚C.  
Nanodrop 
Nanodrop spectroscope was used to measure the plasmid DNA concentration (in ng/µl). First, blanked 
with 1.5 µl of MilliQ water before testing each DNA sample. Concentration (ng/µl), 260/280 and 
260/230 ratios were recorded. 
2.2.4 Tissue Culture 
Resuscitation of cells 
1 ml of frozen HEK-293 GnTI- cells were thawed rapidly at 37 ˚C and added to 9 ml of complete DMEM-
F12 media (500 ml DMEM-F12, 50 ml Heat Inactivated FBS, 5 ml PenStrep, 5 ml L-Glutamine) in a 15 
ml centrifuge tube. Cells were then centrifuged at 1000 rpm for four minutes. The supernatant was 
then removed, and the cells resuspended in 10 ml of DMEM-F12 media before being added to a 10 cm 
culture plate and placed into an incubator at 37 ˚C and 5% CO2 to grow.  
Sub culturing- DMEM-F12 media and trypsin. 
Two sterile cell culture plates were labelled and prepared with the appropriate amount of media for 
the dilution factor. The DMEM-F12 media from the original plate was aspirated off and the plate was 
washed with 5-10 ml of 1x PBS (to ensure all media had been removed). The PBS was then aspirated 
off and 1 ml of trypsin (preheated to 37 ˚C) was added to the plate (made sure to cover the entire 
plate) and incubated for one minute in the incubator (37 ˚C, 5% CO2). 9 ml of DMEM-F12 media 
(preheated to 37 ˚C) was then added to neutralise the effect of trypsin. Using a 10 ml pipette and 
pipette aid, the cells were reverse pipetted 10 times to achieve a cell monolayer. After this, the 
correct amount of cells (and media) were added to the new plates.  
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Freezing cells 
Freezing media was comprised of 10% sterile HybriMax DMSO and 90% DMEM-F12 media (amounts 
depend on total volume of freezing media created).  
Cells were split via the normal subculture technique, transferred to a 15 ml centrifuge tube and 
centrifuged at 1000 rpm for four minutes. The supernatant was removed via aspiration and replaced 
by the freezing media for resuspension. This was then aliquoted into 1 ml per cryovial (total volume 
used was equal to the volume placed into the cryovials) and stored in Styrofoam boxes at -70 ˚C 
before being moved to liquid nitrogen.  
2.2.5 Transfection Protocols 
All conditions and reagent concentrations stated have been optimised for the transfection protocols. 
Buffer Solutions 
2x Bes Buffer (100 ml, for transfections)- 50 mM Bes, 250 mM NaCl, 1.5 mM NaHPO4 [pH 7.02] with 
NaOH 
The correct amount of each component was mixed together in a glass beaker using a magnetic mixing 
flea. NaOH was then added dropwise to the solution until the pH reached 7.02 (measured using a 
calibrated pH meter). This was then filter sterilised and stored as 20 ml aliquots at -20 ˚C.  
10x CaCl2 (100 ml) 
36.7 g CaCl2 (2.5 M) was dissolved in 100 ml distilled water. The solution was then filter sterilised and 
stored as 20 ml aliquots at-20 ˚C.  
Scaling up 
On the Friday before beginning the transfections, the small 10 cm cell culture dishes were scaled up to 
the larger 15 cm cell culture dishes. The process was exactly the same as the subculture technique, 
with the only difference being that more media was used to cover the larger plate (therefore 
accommodating a greater number of cells).  
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Transfection Stage 1 (Dish preparation) Monday 
The media was removed from one of the 15 cm plates and washed with 20 ml of 1x PBS. The PBS was 
then aspirated off and 2 ml of trypsin was added before incubating for two minutes (in incubator  
37 ˚C, 5% CO2). 8 ml of complete DMEM media was added and the cells evenly suspended by pipetting 
up and down multiple times. 10 ml of the plate’s media was then added to 82 ml of complete DMEM 
media in a sterile 250 ml Duran bottle and gently swirled to mix. 9 ml was then added to each cell 
culture plate and then incubated at 37 ˚C and 5% CO2 for 24 hours. NOTE: This is for creating 10 plates, 
each with 9 ml of media and cells. Amounts would need to be adjusted for different plate numbers 
and different cell confluencies.  
Transfection Stage 2 (Seeding cells) Tuesday 
After 24 hours, the cells were transfected with the mutant DNA. The transfection cocktails contained; 
27 µg of DNA, 3 µg of pRSV T-ag and 450 µl of MilliQ water (this is for a single plate, so amounts would 
have to be adjusted to accommodate for more). To each cocktail mixture, 50 µl of 10x CaCl2 was 
added whilst vortexing, followed by 500 µl of 2x Bes buffer whilst vortexing over 45 seconds (again, 
amounts equate to a single plate). 1 ml of the transfection cocktail was then added to the plate and 
incubated at 37 ˚C, 1% CO2 for 24 hours. Fine black precipitates were visible soon after transfection. 
1% CO2 was used to slow down precipitate formation for maximum DNA uptake. Additional pRSV T-ag 
was added to increase pMT4 plasmid replication (as the plasmid contains a SV40 promoter region). 
Transfection Stage 3 (Washing cells) Wednesday 
Complete DMEM media was aspirated off (this was done very carefully as to not disturb the cells), and 
the cells were washed with unsupplemented DMEM media. This media was added slowly to keep the 
cells attached to the plate (marked the spot of addition). The unsupplemented DMEM media was 
removed and replaced by complete DMEM before being placed into the incubator again (37 ˚C, 5% 
CO2, 48 hours).  
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Transfection Stage 4 (Harvesting) Friday 
All transfected plates were removed from the incubator and a scraper was used to detach the cells 
from the bottom of the culture plate and a pipette with pipette aid was used to suspend the cells in 
the media. The media and cells were then transferred to a 15 ml centrifuge tube and centrifuged at 
4500 rpm, 4 ˚C for five minutes. The DMEM media was then removed and replaced by 10 ml PBS and 
the cells resuspended, before centrifugation. Once centrifuged, the PBS was removed, and the cells 
suspended in 450 µl of PBS with 1 µl of PMSF.  
In the dark room (use safe red lights only) 
1 µl of 10 mM 11-cis-retinal in ethanol was added to the suspended cells and incubated at 4 ˚C for two 
hours with constant nutator mixing before being snap frozen in liquid nitrogen and stored at -80 ˚C.  
Rescue Transfections 
The process of these transfections was exactly the same as mentioned before, except after the wash 
stage 9-cis-retinal was added to the cell plates and then wrapped in foil to prevent any exposure to 
light. 20 µM 9-cis-retinal in 0.9 ml ethanol was evaporated under argon before being dissolved in 95 µl 
of filter sterilised DMSO to give a final concentration of 10 µM. 10 µl of 9-cis-retinal dissolved in DMSO 
was added to each plate, wrapped in foil and returned to 37 ˚C, 5% CO2 incubator as normal.  
Stable Cell-line 
A stable cell-line (HEK 293S-GnTI-Rho) was used to create large amounts of WT Rhodopsin protein via 
the same conditions as stated above for passaging, along with the antibiotic Geneticin (200 µg/ml). 
Cells were induced using Tetracycline (20 µl of 2 µg/ml) and Sodium Butyrate (50 µl of 5 mM) before 
being left for three days and harvested in the same way as transfected cells.  
2.3 Purification of rhodopsin Biochemical and Spectroscopic Analysis  
2.3.1 Immunoaffinity Purification 
Once the cells had been harvested following transfection (usually 9 x 10 cm plates or 4 x 15 cm plates 
per protein sample and suspended in 5 ml 1x PBS) a 500 µl aliquot (solubilised with 50 µl 10% DDM 
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and mixed for an hour) was taken and photobleached to determine the total amount of protein 
produced (normalised bleached spectra was taken away from normalised dark spectra to give rough 
estimate of protein concentration). The remaining 4.5 ml sample (or relative amount needed to 
contain approximately 100 µg of protein) was solubilised with 1% DDM and mixed in the dark at 4 ˚C 
for an hour. This was followed by a centrifugation for 20 minutes at 4000 rpm, before the supernatant 
was removed and added to 200 µl of 1D4-sepharose bead slurry (50:50 beads to slurry, binds to the 
TETSQVAPA sequence in C terminus of the rhodopsin protein) and mixed for two hours. After mixing, 
the sample was poured into a 2 ml polystyrene filter column (with frit) and allowed to filter through. 
The column was then washed by 1x PBS/0.1% DDM overnight and 10 mM BTP/0.1% DDM the 
following day. For rescued samples; 100 ml of 1x PBS wash, 150 ml low salt BTP wash and 30 ml high 
salt BTP wash were used.  After the washes, the samples were eluted using 10 mM BTP/0.1% DDM/1% 
Rho 9mer Elution peptide (200 µl instantly for the first elution and 500 µl after 50 minutes for the 
other four elutions). High salt elutions can also be taken to elute misfolded proteins (the same as 
above except containing 140 mM NaCl). All respective samples taken were centrifuged (4 ˚C, 14000 
rpm, 25 minutes) and then tested with the spectrophotometer to record how much protein had been 
eluted and whether the elution was pure.  
2.3.2 UV-visible absorption Spectroscopy 
Once the cells had been thawed (in darkness) 50 µl of 10% DDM was added and the sample nutator 
mixed for an hour at 4 ˚C. Following this, the samples were transferred to non-autoclaved Eppendorf 
tubes and centrifuged for 30 minutes at 14000 rpm, 4 ˚C (pre-cooled microcentrifuge beforehand). 
Blanks were created using 500 µl 1x PBS and 50 µl 10% DDM. The spectrophotometer was loaded 
correctly with a water bath circulator set to 19 ˚C (checked with a thermocouple) and setup with data 
collection between 250 and 650 nm. The cuvettes were cleaned via vacuum suction with 1% SDS, then 
RO water and finally absolute ethanol. Both cuvettes were filled with the blank solution and the 
spectrophotometer autozeroed (checked reading and repeated until zero baseline was achieved). 
Each sample was then run with a blank comparison (in darkness) and then photobleached with light 
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for 45 seconds. Each sample was then returned to its Eppendorf tube and frozen again for use in SDS-
PAGE and western blots.  
2.3.3 SDS-PAGE and Western Blot 
Making the gel: 
The gel rig apparatus and glassware (with 10 well comb) were washed with 1% SDS, absolute ethanol 
and RO water before being dried with Kimtech tissues and assembled. Resolving gel was made up of; 
2.65 ml Acrylamide, 2 ml 4x Running buffer, 80 µl 10% SDS, 3.2 ml MilliQ water, 80 µl APS, 4 µl TEMED 
and inverted to mix. 3 ml was then added to each gel rig and overlaid with 0.5 ml iso-butanol and left 
to polymerise. Once polymerised, the gels were rinsed with RO water and dried with blotting paper. 
The gel rig was then overflowed with the stacking gel (0.7 ml Acrylamide, 1.13 ml 4x stacking buffer, 
60 µl 10% SDS, 2.7 ml MilliQ water, 60 µl APS and 4 µl TEMED) and the comb inserted.  
Running the gel: 
The electrode assembly was set up (as per the manufactures’ instructions) and placed into the running 
tank. The upper chamber filled with 1x Tank buffer and left for a few minutes to check that there were 
no leaks. A syringe and lancet were used to clear out the wells formed of any non-polymerised gel. 
The samples were loaded from right to left; 6 µl of Ladder sample (5 µl ladder sequence and 1 µl 1x 
Loading buffer) and then 6 µl of each sample (12 µl of sample and 4 µl 4x Loading buffer) were added 
to the appropriate wells. The lower chamber was then filled with 1x Tank buffer and run for an hour at 
200 V.  
Coomassie blue staining: 
One gel was removed and rinsed with RO water before being incubated in instant blue staining 
solution for an hour at room temperature with constant rotator mixing or until the bands became 
visible. The gel was then left overnight in the staining before being placed on a light box and 
photographed.  
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Western blot: 
Cold transfer buffer was used to soak the other gel, cassette, blotting paper (4 pieces), nitrocellulose 
and sponges. They were then assembled as follows: black cassette side, sponge, two pieces of blotting 
paper, nitrocellulose, gel, two pieces of blotting paper, sponge, and all air was removed by using a 
roller before closing the array. Once closed, the black cassette side was placed facing the red positive 
transfer frame, an ice pack and magnetic stirrer were also placed into the tank and filled with the 
transfer buffer. The western blot was run at 100 V for an hour and the tank placed onto a stirring plate 
inside a bucket of ice. Afterwards, the blot was placed into a box and covered in blocking buffer, then 
incubated overnight at 4 ˚C with constant rotator mixing. The following morning, the membrane blot 
was washed with PBS and incubated for five hours in the primary antibody. After this, the blot was 
washed five times every five minutes with 50 ml of wash buffer. Once washed, the blot was incubated 
for an hour in the secondary antibody with rotator mixing. The blot was again washed five times with 
the wash buffer before incubating in 10 ml ECL reagents (10 ml 0.1 M Tris-HCl [pH 8.5], 50 µl 0.25 M 
Luminol, 22 µl 0.01 M Courmic Acid, 3 µl 30% H202) for one minute. Excess ECL was blotted away and 
the blot wrapped in clingfilm with no air bubbles (tissues were used to remove and flatten) before 
being tapped to the radiographic cassette. IN THE DARK ROOM a piece of film was cut into four 
equally sized pieces and four trays were filled with photographic developer, photographic fixer or two 
with RO water. One piece of film was exposed to the blot in the cassette (time varied depending on 
the sample) before being placed in the developer until bands started to form. The film was then 
washed in RO water before being placed into the fixer. Once fixed, the film was washed again and left 
to air dry and repeated with other film pieces. Alternatively, once the ECL reagents had been added 
and the blot wrapped in clingfilm, a fluorescent imager was used to take digital photos of the blot. A 
chemiluminescence setting was used to highlight the protein bands and a blot marker setting to 
highlight the ladder sequence, before both images were merged together to create a whole western 
blot image.  
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2.3.4 Rhodopsin Photobleaching 
An aliquot of the sample, equal to an absorbance of 0.02 AU or 20 µg, was made up to 500 µl in  
10 mM BTP/0.1% DDM and centrifuged for 20 minutes. The sample then underwent a standard 
photobleaching reaction for 30 seconds, at 20 ˚C from a water bath circulator, where both dark and 
bleached spectra were recorded. Following this, 3 µl of 2 M sulphuric acid (H2SO4) was added to the 
sample and blank. Then the acidified spectra were measured. All three spectra were then combined 
together on a single graph.  
2.3.5 Rhodopsin Active State (Meta-II) Decay 
An aliquot of the sample, equal to 4 µg of protein, was made up to 600 µl in 10 mM BTP/0.1% DDM 
and centrifuged for 20 minutes. The sample was then placed in a fluorometer, with water bath 
circulator set at 20 ˚C, for two hours. The sample was exposed to light at a wavelength of  
250 nm and emitted at an excitation wavelength of 380 nm. The data was then recorded and used in 
SigmaPlot to create a graph with a single component exponential decay curve and calculated the half-
life. 
2.3.6 Rhodopsin Thermal Stability 
An aliquot of the sample, equal to an absorbance of 0.02 AU or 20 µg, was made up to 500 µl in  
10 mM BTP/0.1% DDM and centrifuged for 20 minutes. The UV-Visible spectrophotometer was 
blanked at room temperature before being heated to 55 ˚C using a water bath circulator (checked 
using a thermocouple). The sample, kept in darkness, was then placed in the spectrophotometer and 
the absorbance (between 250 and 650 nm) was measured every five minutes for the first hour and 
then every 30 minutes for the next 24 hours. The data was then recorded and used in SigmaPlot to 
create a decay graph with a single component exponential decay curve and calculated the half-life.  
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3. Results 
3.1 Verification of the DNA sequence for Retinitis Pigmentosa mutation in the rhodopsin gene 
At the onset of this project it was necessary to confirm the identity of all rhodopsin mutants by DNA 
sequencing. For this Escherichia coli XL1-Blue strain was transformed with pMT4 plasmids that 
contained the following RP mutations: WT, WT N2C/D282C, G101V, G101V N2C/D282C, V104F, V104F 
N2C/D282C, G106W and G106W N2C/D282C. The pMT4 plasmid is the same as that used by Franke et 
al., 1988 except the pMT2 vector now contains a rhodopsin gene sequence. This was completed and 
followed up by growing the bacterial colonies in small culture volumes (approximately 1 ml) and then 
small-scale preparation of the plasmids (see Methods- Culturing Techniques). Table 3.1 shows the 
yield and UV absorbance properties of the purified samples. 
Table 3.1- Initial DNA concentrations and spectral properties. Data recorded using a Nanodrop 1000 Spectrophotometer to 
measure mutant DNA concentrations and give their respective spectral properties. 
Rhodopsin Mutant DNA Concertation 
(ng/µl) 
260 nm/280 nm 
 
260 nm/230 nm 
 
WT 160.2 1.89 2.34 
WT N2C/D282C 162.4 1.92 2.31 
G101V 145.1 1.89 2.30 
G101V N2C/D282C 150.4 1.89 2.28 
V104F 180.5 1.91 2.32 
V104F N2C/D282C 142.6 1.88 2.27 
G106W 161.6 1.93 2.35 
G106W N2C/D282C 157.6 1.91 2.38 
 
These results show that all plasmids gave good DNA yields at a high purity (260 nm/280 nm ~1.8 ml). 
These plasmids were then subjected to restriction enzyme digestion followed by separation of the 
fragments by agarose gel electrophoresis (Methods- Agarose Gel Electrophoresis). Here the restriction 
digest was performed using EcoRI and NotI together. As a control the undigested plasmids were also 
loaded onto the agarose gel. The results are shown below in Figure 3.1. The largest band from the 
undigested samples is about 8000 bp (base pairs) in size, whilst the smaller band is about 4000 bp. The 
EcoRI-NotI digested plasmids result in two DNA fragments of roughly 5000 bp and 1000 bp. When the 
agarose gel is compared to the plasmid map in Figure 3.2 (created using SnapGene and SnapGene 
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Viewer), the estimated band sizes are comparable. The total size of the Bovine Rhodopsin gene is 1048 
bp and, taking into account the locations of the EcoRI and NotI restriction sites, the small fragments 
shown on the agarose gel below are 1058 bp in size (the restriction sites sit either side of the 
rhodopsin gene). The EcoRI site is located between base pairs 1061 and 1066, whereas NotI restriction 
site is between base pairs 2117 and 2125. As the total plasmid size is 6186 bp, then the large fragment 
must be 5128 bp in size. These actual sizes are very similar to the estimations made from the agarose 
gel of 1000 bp for the small fragment and 6000 bp for the large fragment (even numbered lanes). The 
odd numbered lanes (undigested plasmids) show bands at 4000 bp and 8000 bp, in line with the 
various relaxation states of non-linearised plasmids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1- Restriction digest pattern of pMT4 plasmids containing mutant rhodopsin genes. Odd numbered lanes were 
loaded with undigested plasmids, whereas even numbered lanes were loaded with plasmids digested by EcoRI and NotI 
restriction endonucleases. DNA fragments were then separated by agarose gel electrophoresis (Methods- Agarose Gel 
Electrophoresis). Samples were then loaded as follows: 1-2 WT; 3-4 WT N2C/D282C; 5-6 G101V; 7-8 G101V N2C/D282C; 9-10 
V104F; 11-12 V104F N2C/D282C; 13-14 G106W and 15-16 G106W N2C/D282C. The DNA ladder is loaded as indicated.  
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Figure 3.2- pMT4 Bovine Rhodopsin Gene plasmid map. Complete pMT4 plasmid map diagram showing the representative 
locations of the wildtype bovine rhodopsin gene (blue region between 1051 bp and 2171 bp) as well as the restriction 
endonuclease sites for EcoRI (at 1061 bp) and NotI (2119 bp), both highlighted in orange boxes. Other significant aspects are 
also shown including the origin of replication, ampicillin resistance gene and Adenovirus MLP. The total number of base pairs 
for the entire plasmid is also stated at 6186 bp. This diagram was created using SnapGene and visualised using SnapGene 
Viewer.  
 
Following on from the confirmation that all plasmids had the correct restriction pattern mutants, the 
plasmids were subjected to Sanger sequencing. Sequencing reactions were performed with rhodopsin 
sequencing primers F1 and F2 labelled in purple (F1 sequence: 5’ GGT GTG GCA GGC TTG AGA TC 3’ 
and F2 sequence: 5’ GTG TGC AAG CCC ATG AGC AAC 3’).  
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Figure 3.3- Wildtype rhodopsin and N2C residue mutant sequence alignment. Sequence alignments were created using the 
online EMBOSS needle website and the corresponding chromatograms were created using Finch TV. The sequence alignment 
displays a comparison between a wildtype rhodopsin sample (named as 1_F1) and N2C mutation (named 2_F1). Highlighted 
in black are the base differences at positions which correspond to amino acid 2. Amino acid 2, Asparagine (N) has been 
replaced by Cysteine (C). The chromatogram on top shows the sequences for the wildtype rhodopsin, whereas the 
chromatogram underneath shows the sequence of N2C variant. Orange arrows highlight the Methionine start codon (ATG) 
and the direction of translation.  
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Figure 3.4- Wildtype rhodopsin and D282C mutant sequence alignment. Sequence alignments were created using the online 
EMBOSS needle website and the corresponding chromatograms were created using Finch TV. The sequence alignment 
displays a comparison between a wildtype rhodopsin sample (named as 1_F1) and D282C mutation (named 2_F1). 
Highlighted in blue are the base differences at positions which correspond to amino acid 282. Amino acid 282, Aspartic acid 
(D) has been replaced by Cysteine (C). The chromatogram on top shows the sequence for the wildtype rhodopsin, whereas 
the chromatogram underneath shows the sequence of the D282C variant. 
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Figure 3.5- Wildtype rhodopsin and RP rhodopsin mutant sequence alignment comparisons. Sequence alignments were 
created using the online EMBOSS needle website and the corresponding chromatograms were created using Finch TV. Part A 
shows a magnified area of the WT rhodopsin sequence showing the original codons that make up residues 101 (yellow), 104 
(red) and 106 (green). Part B shows a sequence comparison for WT rhodopsin (1_F1) against G101V (3_F1) and the 
chromatogram shows the codon for G101V. Part C shows a sequence comparison for WT rhodopsin (1_F1) against V104F 
(5_F1) and the chromatogram shows the codon for V104F. Part D shows a sequence comparison for WT rhodopsin (1_F1) 
against G106W (7_F1) and the chromatogram shows the codon for G106W.  
 
A 
B 
C 
D 
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Figures 3.3 through 3.5 have been created using the online sequence alignment website EMBOSS 
needle (https://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html) and the chromatograms 
using the software program Finch TV. Figures 3.3 and 3.4 show the sequence alignments between a 
wildtype rhodopsin sample (labelled as 1_F1) and the rhodopsin N2C/D282C mutant (labelled as 2_F1) 
(see Introduction- Aims and Hypotheses). These differences are highlighted in black and blue. The 
black ovals and rectangle in Figure 3.3 show the differences for the mutation at amino acid codon 2, 
where Asparagine has been replaced by Cysteine (genetic sequence has changed from AAC to TGC, 
shown in the chromatograms from top to bottom). The blue ovals and rectangle in Figure 3.4 show the 
same but for mutations at amino acid 282, where Aspartic Acid has been replaced by Cysteine (genetic 
sequence has changed from GAC to TGC, shown in the chromatograms from top to bottom). Figure 3.5 
shows similar comparisons between the wildtype rhodopsin (labelled 1_F1) and the three single 
mutations being examined in this project. Figure 3.5 part A is a magnified area which shows the non-
mutated WT rhodopsin codons for the mutations: G101V, V104F and G106W highlighted in their 
respective colours. Figure 3.5 part B shows a sequence alignment between the wildtype and G101V 
mutant (labelled 3_F1) with the base differences highlighted in yellow. The amino acid Glycine has 
been replaced by Valine and the codon has changed from GGG to GTC. Figure 3.5 parts C and D show 
the same but for V104F (labelled 5_F1) in red and G106W (labelled 7_F1) in green. For the V104F 
mutant, Valine has been replaced by Phenylalanine with the codon changing from GTC to TTC. 
Whereas for the G106W mutant, Glycine has been replaced by Tryptophan with the codon changing 
from GGG to TGG.   
 
3.2 Medium and Large-scale plasmid DNA preparation  
Plasmids containing the correct rhodopsin mutations were used for medium scale DNA preparation for 
use in mammalian cell transfections. Tens of microgram amounts of DNA were needed to transfect 
mammalian cells (1x107 cells on a 10 cm dish) on multiple occasions to generate results with biological 
replicates.    
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Large volume E. coli XL1 Blue cultures (100 ml) were grown (Methods- Culturing techniques) and used 
for large scale (MidiPrep) plasmid purifications to create larger amounts of DNA (~1 mg) to be used for 
transfection of mammalian cells (see Methods- DNA Extractions and Transfections).  
Plasmids were prepared in 500 µg to 1 mg amounts with acceptable spectral properties indicating high 
purity.    
 
3.3 Expression levels of ADRP rhodopsin mutants examined using UV-visible absorbance 
spectroscopy  
Disulphide Bridge mediated Repair and Pharmacological Chaperone Rescue 
RP mutations in the extracellular region of rhodopsin often lead to misfolding and/or instability 
(Athanasiou et al., 2018). Here we designed experiments to determine whether this set of mutants 
misfold upon expression in HEK 293S GnTI- cells and, if so, if the misfolding could be reversed or 
reduced by applying a N2C/D282C disulphide bridge bond repair strategy or by pharmacological 
chaperone rescue treatment with the ligand 9-cis-retinal during expression (Introduction- Figure 1.10). 
In all rescue transfection experiments, the cells were treated after harvest with 9-cis-retinal (non-
transfected treated with 11-cis-retinal) in order to convert the rod opsin apoprotein to the rhodopsin 
pigment (λ max vis = 500 nm) formation. 
The first set of experiments were designed to measure rhodopsin pigment expression levels for each 
RP mutant in the rhodopsin background or the N2C/D282C background (see Methods- UV-visible 
absorption Spectroscopy). 
These experiments were repeated three times using HEK 293 GnTI- cells grown on 10 cm cell culture 
dishes (Methods- Tissue Culture). Similar experiments were also conducted to observe whether 
pharmacological chaperone rescue makes any difference in the amount of protein produced by the 
presence of a mutation (with a WT control). For this to occur, 9-cis-retinal is added to the cell plates 
during the transfection stages and wrapped in foil to prevent them being exposed to light (see 
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Methods- Rescue Transfection). Both experiments were also performed together to see whether 9-cis-
retinal treatment can have an additive effect when in the N2C/D282C background.  
The expression level of each mutant pigment was determined using detergent solubilised clarified cell 
extracts spectroscopy. The expression levels are presented in Figures 3.6 and 3.7.   
 
 
Figure 3.6- RP mutant rhodopsin protein production after pharmacological rescue or N2C/D282C mediated repair. Graphs 
showing the average amount of protein produced by RP mutant rhodopsin proteins compared with either the rhodopsin 
protein rescued by 9-cis-retinal treatment or in the N2C/D282C background, with WT controls (n=3). Blue columns represent 
untreated RP mutants, orange columns represent 9-cis-retinal rescued RP mutants and grey columns represent N2C/D282C 
repaired RP mutants. Each pair has a calculated p-value from a two tailed t-test to show any significant difference. *- p<0.05 
for RP vs rescued or repaired counterpart (e.g. WT rhodopsin vs. Rescued WT or WT N2C/D282C).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 * 
* * 
* 
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Figure 3.7- RP mutant rhodopsin protein production after pharmacological rescue or N2C/D282C mediated repair. Graphs 
showing the average amount of protein produced by RP mutant rhodopsin proteins compared with either the rhodopsin 
protein rescued by 9-cis-retinal treatment or in the N2C/D282C background, including N2C/D282C rescued mutants and WT 
controls (n=3). Blue columns represent untreated RP mutants, orange columns represent 9-cis-retinal rescued RP mutants, 
grey columns represent N2C/D282C repaired RP mutants and yellow columns represent rescued & repaired mutants. Each 
pair has a calculated p-value from a two tailed t-test to show any significant difference. *- p<0.05 for rescued RP vs rescued 
N2C/D282C. 
 
From the first graph shown in Figure 3.6, we can see that the RP mutant (blue columns) pairs have 
produced statistically different amounts of rhodopsin pigment when 9-cis-retianl is present during 
expression (orange columns). Non-rescued WT produces around 20 µg of protein but once rescued 
this drops to nearly 11 µg. A similar pattern can be seen with V104F which drops from 16 µg when 
non-rescued to less than 10 µg once rescued. On the other hand, both G101V and G106W show 
increased rhodopsin pigment formation once rescued, from 4 µg to 6 µg for G101V and 2 µg to about 
6 µg for G106W. Each mutant pair was compared using a two tailed t-test and all were found to be 
statistically different with a p-value less than 0.05 (5%).  
From the second graph in Figure 3.6, we can see the difference between RP mutants (blue columns) 
and in the context of the N2C/D282C rhodopsin background (grey columns). WT and V104F both show 
a decrease in protein production from 20 µg to 13 µg for WT to WT N2C/D282C and 16 µg to 14 µg for 
V104F to V104F N2C/D282C. G101V shows an increase in rhodopsin pigment formation from 4 µg to 
approximately 8 µg for G101V N2C/D282C, which is similar to G106W increasing from 2 µg to 8 µg 
 
* 
* 
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when repaired. A comparison using a two tailed t-test shows that WT - WT N2C/D282C, G101V - 
G101V N2C/D282C and G106W - G106W N2C/D282C are statistically different with a p-value of less 
than 0.05 (5%). Whereas V104F - V104F N2C/D282C has a p-value of greater than 0.05 (5%) indicating 
that this RP mutant pair is statistically similar.  
Using all of the data in Figures 3.6 and 3.7, both rescue with 9-cis-retinal treatment and repair with a 
N2C/D282C disulphide bridge increase protein expression for G101V and G106W but reduce pigment 
production for WT and V104F. However in each case, more rhodopsin pigment is produced by the 
repaired N2C/D282C mutants than those rescued by 9-cis-retinal treatment. In Figure 3.7 the yellow 
columns denote RP mutants that have been subjected to simultaneous pharmacological chaperone 
rescue and disulphide bond repair. Each rescued-repaired mutant produces less pigment than solely 
repaired mutants (grey columns) and solely rescued mutants (orange columns) except for G106W. The 
only instance where rescue and repair methods have an additive effect is for G106W at 7 µg, but this 
is still lower than G106W N2C/D282C at 8 µg. Overall; WT rhodopsin production is hindered by both 
rescue and repair, G101V is enhanced by both rescue and repair but has no additive effect, V104F is 
hindered by both rescue and repair and finally G106W is enhanced by both recue and repair with a 
slight additive effect.  
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3.4 Analysis of RP mutant rhodopsin biochemical properties and spectral characteristics 
3.4.1 Examination of protein profiles rhodopsin ADRP mutants as judged by SDS-PAGE 
Solubilised cell lysates containing the rhodopsin mutants were loaded onto SDS-PAGE gels. Total 
protein content was visualised by staining the gels with Coomassie blue while western blotting uses 
the Rho-1D4 monoclonal antibody (Methods- SDS-PAGE and Western Blots). The Coomassie blue dye 
binds to and stains all proteins present in the sample and is used as a loading control only. Western 
blotting with Rho-1D4 recognises and binds to the TETSQVAPA sequence which corresponds to amino 
acids 340 to 348 in rhodopsin’s C-terminal (see Introduction- Figure 1.4). From the western blots, the 
most vivid protein bands are estimated to be between 35 and 40 kDa (kilo-Daltons), which is 
consistent with the size of rhodopsin solubilised in DDM. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8- Coomassie Instant Blue stained polyacrylamide gels of various mutant rhodopsin proteins. Photos of 
polyacrylamide gels stained with Coomassie blue dye. All gels show three repeats of three different samples (post 
photobleaching) and a prestained ladder sequence in the first lane. Gel A shows Untransfected cell proteins, WT proteins and 
unstable WT proteins (from left to right). Gel B shows WT, G101V and G101V N2C/D282C. Gel C shows WT, V104F and  
V104F N2C/D282C. Gel D shows WT, G106W and G106W N2C/D282C.  
 
 
 
 
 
A 
170  
70 
40 
10 
C 
170 
70 
40 
10 
D 
40 
70 
170 
10 
B 
170 
10 
40 
70 
kDa  
kDa  
kDa  
kDa  
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9- ECL fluorescent image western blot images of various mutant rhodopsin proteins. Images of western blot 
membrane treated with Enhanced Chemiluminescence reagents. All of the membranes show three repeats of three different 
samples (post photobleaching) and a prestained ladder sequence in the first lane. Blot A shows Untransfected cell proteins, 
WT rhodopsin and WT rhodopsin in N2C/D282C background (from left to right). Blot B shows WT rhodopsin, Rho G101V and 
G101V N2C/D282C.  Blot C shows WT rhodopsin, Rho V104F and V104F N2C/D282C. Blot D shows WT rhodopsin, Rho G106W 
and G106W N2C/D282C. WT and RP mutants show glycoforms of rhodopsin; I- nonglycosylated species, II- major species 
containing initial N-glycan (GlcNAc3Man3GlcNAc2), III- trimming intermediate (Reeves et al., 2002).  
 
There is very little difference between the lowest bands displayed in each western blot in the figure 
above, however the three lanes that contain the relevant RP rhodopsin mutants in the N2C/D282C 
background are noticeably, albeit slightly, lower than the lanes containing WT rhodopsin or RP 
rhodopsin mutants (G101V, V104F and G106W). The size of the native rhodopsin protein, estimated 
from the western blots, appears to be in the region of 35 to 40 kDa, most likely sitting in the middle at 
about 37 kDa. This is for the WT and non-repaired RP mutant samples only as all of the repaired RP 
mutant sample bands are lower sitting at around 35 kDa, along with dimer (species II) and trimer 
(species III) rhodopsin glycoforms highlighted in Figure 3.9 part A. The trimming intermediate refers to 
the conversion of Man9GlcNAc2 to Man5GlcNAc2 (Reeves et al., 2002). This drop in protein size is due 
to the substituted Asn2 residues that create said bridge removing a site for glycosylation. The true 
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molecular mass of rhodopsin when glycosylated and bound retinal is 42 kDa (Takeda and Haga, 2005), 
however runs through a PAGE gel faster with SDS bound so appears smaller.  
3.4.2 Purification of RP mutant pigments 
The western blots below in Figure 3.10 show rhodopsin samples that have been purified by Rho-1D4 
immunoaffinity chromatography (Methods- Immunoaffinity Purification). Both the PBS and BTP 
washing steps contain virtually no rhodopsin signal. The photobleached mutant samples look no 
different to those shown in Figure 3.8. All of the following lanes representing elutions, both low and 
high salt, contain rhodopsin. The largest amount of rhodopsin can be seen in low salt elution 2 (red 
arrow), each of which was considered to be pure with a 280 nm to 500 nm ratio of 1.6:1.  
The larger transfections and purification process have been repeated when necessary to produce 
enough protein to perform experiments in replicate (see Methods- Transfections).   
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Figure 3.10- Western blot images of purified RP mutant rhodopsin proteins. Images of western blot membranes treated 
with Enhanced Chemiluminescence reagents. Membranes show a prestained ladder sequence in the first lane, followed by a 
rhodopsin sample. Moving towards the right, the lanes contain the protein flow-through, PBS and BTP washes followed by 
both low and high salt elutions. The second low salt elutions (highlighted by a red arrow) are considered pure. 
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3.4.3 Photobleaching properties of the immunoaffinity purified rhodopsin mutants  
The non-photobleached rhodopsin sample (blue line) has a peak visible absorbance at 500 nm that 
upon exposure to light (30 seconds, >495 nm as described in Methods- Rhodopsin Photobleaching) is 
converted to a 380 nm form (orange line). Following the addition of sulphuric acid this peak then 
moves to about 440 nm (grey line), consistent with the Retinylidene-Schiff base at Lysine residue 296 
becoming protonated. All of the spectra in Figure 3.11 below show a similar photobleaching profile. 
There is little difference between the non-repaired mutant proteins (WT, G101V, V104F and G106W) 
and their repaired counterparts (with the N2C/D282C background mutation). The only two that do not 
fit this trend are G101V and G106W, as these two were rescued with 9-cis-retinal to obtain a usable 
amount of pure protein (refer back to Figure 3.6 to see how rescuing increased G101V and G106W 
protein expression) and unbound retinal has remained within the eluted solution after washing. 
G101V and G106W show a partial 440 nm peak, whereas G101V N2C/D282C and G106W N2C/D282C 
have photobleached correctly. The clearly visible absorbance peak at 440 nm shows that the retinal 
molecules present are attached to the rhodopsin protein via a protonated Schiff base.  
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Figure 3.11- UV-visible absorbance spectrographs for dark state, photobleached and acidified RP mutant pigments. Purified 
pigments (blue line) were exposed to light for 30 seconds (orange line) before being acidified using H2SO4 (grey line), all 
measured using a UV-visible spectrophotometer.  
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3.4.4 Photoactivation of purified ADRP pigments followed by observation of Meta-II Decay 
Active State Decay (or Meta-II Decay) experiments were carried out in order to monitor the stability of 
the active Meta-II form of rhodopsin (Methods- Rhodopsin Meta-II Decay). Exposure to light results in 
the isomerisation of 9-cis-retinal to all-trans retinal and activates rhodopsin to the Meta-II state. The 
protonated Schiff base releases the unstable all-trans retinal from the Meta-II rhodopsin, and the 
resulting energy excites nearby tryptophan molecules and increases their fluorescence. This increase 
in fluorescence rises to a plateau where the Meta-II rhodopsin molecules have fully decayed. The data 
was fitted with a single component exponential decay curve, which was used to calculate the half-life 
of the protein sample.  
From Figure 3.12 it is observed that the Meta-II decay kinetics fit well to a single component. Upon 
photoactivation the rhodopsin Meta-II species decays with a half-life of 13.4 minutes. WT N2C/D282C 
Meta-II decays similarly to WT Meta-II with a half-life of 13.6 minutes. WT and WT N2C/D282C decay 
curves reach a plateau after about 60 minutes under these conditions. G101V and G101V N2C/D282C 
Meta-II species have average half-lives of 4.7 minutes and 9.3 minutes respectively. V104F and V104F 
N2C/D282C Meta-II species are similar to WT (and to each other) at 8.3 minutes and 9.7 minutes 
respectively. G106W and G106W N2C/D282C Meta-II products have half-lives of 8.7 minutes and 11.3 
minutes, respectively. WT Meta-II is the most stable, with both V104F and G106W being less stable 
and G101V being the least stable. 
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Figure 3.12- Active State/Meta-II Decay curves. Single component Meta-II decay curves of WT rhodopsin, RP mutant 
rhodopsin and RP mutant rhodopsin in the N2C/D282C background. Decay curves (n=3) fluorescence increase measured over 
the course of two hours, emission wavelength 250 nm and excitation wavelength 380 nm. Half-lives (minutes) calculated 
using SigmaPlot software. Non-repaired rhodopsin sample are shown in red whilst repaired rhodopsin samples are green.  
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Figure 3.13- Active State/Meta-II Decay Rate constants. Half-lives of rhodopsin RP mutants pigments along with their 
repaired counterparts (N2C/D282C), with WT control for comparison and error bars. *- p<0.05 for t1/2 values compared 
against WT t1/2. 
The data shown in Figure 3.13 highlights that the rhodopsin RP mutant pigments have Meta-II decay 
half-lives that are significantly different to that of WT rhodopsin. Whereas the repaired RP mutant 
pigments (and WT N2C/D282C) are not significantly different, with all repaired pigments potentially 
having a half-life between 10 and 12 minutes.  
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3.4.5 Thermal Stability of Rhodopsin RP mutant pigments 
The thermostability of rhodopsin and its mutants can be measured by monitoring the amount of  
500 nm pigment at elevated temperatures as a function of time. Measurements are recorded using a 
spectrophotometer set to measure the sample’s absorbance every five minutes for the first hour, 
before being changed to measure every 30 minutes for the next 24 hours at a temperature of 55 ˚C 
(Methods- Rhodopsin Thermal Stability). The absorbance at 500 nm was plotted as a function of time. 
The data was normalised and fitted with a single component exponential decay function (Figures 3.14 
to 3.17). Due to the increased thermostability half-lives of the N2C/D282C variants, theoretical 
endpoints (shown by the dotted lines in Figures 3.14 and 3.15) have been used to simulate an 
absorbance of zero. From this endpoint, SigmaPlot has created a curve to fit this using a small data set. 
However, the results are comparable to published data (Opefi et al., 2013). 
WT rhodopsin has a half-life of around 80 minutes at 55 ˚C under the conditions used (Methods- 
Thermal Stability). Over time there is a decrease in absorbance at 500 nm and an increase at 380 nm. 
WT N2C/D282C decays with a longer half-life of 192 minutes (Figure 3.14). For G101V and G101V 
N2C/D282C, their clear differences in pigment thermostability are evident. G101V has a half-life of 
three minutes, whereas the G101V N2C/D282C pigment has a half-life of 67 minutes. For G101V 
rhodopsin there is no pigment remaining after the first ten minutes at 55 ˚C, yet for G101V 
N2C/D282C there is pigment remaining after 400 minutes has passed (Figure 3.15). For V104F, half-life 
of 68 minutes, and V104F N2C/D282C, half-life of 161 minutes, have thermostabilities that are similar 
to that of WT. However, the half-lives of these pigments do differ with V104F N2C/D282C being much 
more stable at 55 ˚C than V104F in the WT rhodopsin background (Figure 3.16). G106W, like G101V, 
decays rapidly at high temperatures and has a half-life of just one minute (Figure 3.17). The presence 
of the N2C/D282C disulphide bridge confers enhanced thermal stability in comparison to the same RP 
mutation in the WT rhodopsin background, increasing half-lives by 22-fold for G101V-G101V 
N2C/D282C and 2.5-fold for V104F-V104F N2C/D282C. 
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Figure 3.14- WT Rhodopsin Thermal Decay plots. Thermal Decay curves measured using a spectrophotometer, set to 55 ˚C 
(Methods- Rhodopsin Thermal Stability). Readings were taken every five minutes for the first hour, followed by every 30 
minutes for the next 24 hours (n=3, spectrograph colours represent different time points). The data was normalised before 
being plotted. Decay curves were plotted and fitted using in SigmaPlot. Curve fitted data was used to calculate rhodopsin 
pigment half-life (minutes) from absorbance at 500 nm (black line). 
Figure 3.15- G101V Non-repaired and repaired mutant Rhodopsin Thermal Decay plots. Thermal Decay curves measured 
using a spectrophotometer, set to 55 ˚C (Methods- Rhodopsin Thermal Stability). Readings were taken every five minutes for 
the first hour, followed by every 30 minutes for the next 24 hours (n=3, spectrograph colours represent different time 
points). The data was normalised before being plotted. Decay curves were plotted and fitted using in SigmaPlot. Curve fitted 
data was used to calculate rhodopsin pigment half-life (minutes) from absorbance at 500 nm (black line). 
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Figure 3.16- V104F Non-repaired and repaired mutant Rhodopsin Thermal Decay plots. Thermal Decay curves measured 
using a spectrophotometer, set to 55 ˚C (Methods- Thermal Stability). Readings were taken every five minutes for the first 
hour, followed by every 30 minutes for the next 24 hours (n=3, spectrograph colours represent different time points). The 
data was normalised before being plotted. Decay curves were plotted and fitted using in SigmaPlot. Curve fitted data was 
used to calculate rhodopsin pigment half-life (minutes) from absorbance at 500 nm (black line). 
Figure 3.17- G106W Non-repaired mutant Rhodopsin Thermal Decay plots. Thermal Decay curves measured using a 
spectrophotometer, set to 55 ˚C (Methods- Thermal Stability). Readings were taken every five minutes an hour (n=3, 
spectrograph colours represent different time points). The data was normalised before being plotted. Decay curves were 
plotted and fitted using in SigmaPlot. Curve fitted data was used to calculate rhodopsin pigment half-life (minutes) from 
absorbance at 500 nm (black line). 
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4. Discussion 
Rhodopsin is a photosensitive GPCR that mediates vision in response to dim light. The rhodopsin gene 
is a genetic hotspot for the majority of adRP cases (Bravo-Gil et al., 2017). Mutations in rhodopsin are 
located throughout the length of the receptor and they have been classified into groups (classes 1 to 
7) on the basis of phenotype (Mendes et al., 2005).  
Three rhodopsin adRP mutants have been the focus of this project: G101V, V104F and G106W. These 
amino acid residues are located in or near extracellular loop 1 (ECL 1) of rhodopsin. This region is in 
close contact with the N-terminal cap of rhodopsin, a structure that was previously implicated in the 
folding, structure and function of rhodopsin (Opefi et al., 2013). The overall aim of this project was to 
examine the importance of ECL 1 as a docking point for the N-terminal cap. In order to answer this 
question the recombinant expression, thermal stability, photoactivation and light activated state 
(Meta-II) stability were measured. These results could provide an insight into the molecular 
mechanism of pathogenesis and provide clues into the fundamental role of ECL 1 in the receptor 
folding and stability. Disulphide bridge mediated repair (N2C/D282C) and pharmacological chaperone 
rescue (9-cis-retinal) were used in an attempt to investigate reporter expression/folding and to obtain 
the mutant rhodopsin pigments for further biophysical characterisation. Similar methods have proved 
successful in other investigations with other rhodopsin RP mutants; such as V209M (valine to 
Methionine), F220C (phenylalanine to Cysteine), P23H (Proline to Histidine) and P267L (Proline to 
Leucine) (Gragg and Park, 2018, Ploier et al., 2016). 
For this project, recombinant HEK 293 GnTI- cells were transfected with a pMT4 plasmid carrying the 
mutant rhodopsin genes (see Methods- Transfections). Difference spectra were calculated from  
UV-visible absorbance spectroscopy data in order to establish relative expression levels of each 
mutant. These mutant pigments were then purified using Rho-1D4 Sepharose resin for their 
characterisation.  
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4.1 Recombinant expression of rhodopsin mutants located in Extracellular Loop 1 (ECL 1) 
Looking back at Figures 3.6 and 3.7 in the results section, we can clearly see that using either  
9-cis-retinal for pharmacological chaperone rescue or inserting a N2C/D282C bond for disulphide 
bridge mediated repair gives a significant increase in the pigment expression of two RP mutants; 
G101V and G106W. Both of these mutants have greater pigment production levels when said methods 
are used independently but have very little additive effect when used together (at least for G106W). 
However WT and V104F rhodopsin pigments do not respond positively to either method as their non-
rescued and non-repaired pigments have the greatest expression levels. The trends visible in these 
results tend to show that repaired pigments have higher expression levels than their non-repaired 
counterparts, rescued pigments have higher expression levels than only non-rescued non-repaired 
counterparts and there does not seem to be any additive effect from using both methods together. 
These trends agree with what has been found in previous studies as pharmacological chaperone 
rescue using 9-cis-retinal corrects the folding of a misfolded protein molecule and stabilises it, as well 
as reducing the misfolded protein’s cytotoxic effects (Bernier et al., 2004, Krebs et al., 2010).  
9-cis-retinal is also thought to help reduce protein aggregation and enhance translocation via the 
secretory pathway (Mendes and Cheetham, 2008). Whilst disulphide bridge mediated repair has been 
found to not interfere with protein activation (Standfuss et al., 2008). Disulphide bridge mediated 
repair has been noted to cause slight reductions in rhodopsin pigment expression levels, most likely 
because it is still a mutation so will have some effect on pigment production (Reeves et al., 2013). 
Expression levels from rescued pigments are reduced, possibly due to the severity of the RP mutations 
or due to the efficiency of pharmacological chaperone rescue, but DMSO has been found to have 
cytotoxic effects on embryonic cells in particular (HEK cells used for this project) (Pal et al., 2012). This 
means that fewer cells are able to express the mutant pigments, leading to lower concetrations. 
However the cytotoxicity effect is overlooked if the pigment is rescued by retinal treatment involving 
DMSO (Figures 3.6 and 3.7, WT & V104F compared to G101V & G106W). 
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4.2 Thermal stability of rhodopsin mutants in ECL 1 
RP rhodopsin mutant pigments have reduced thermal stability properties when compared to WT 
rhodopsin, yet the presence of the N2C/D282C disulphide bridge has been well recorded to show an 
increase in rhodopsin pigment thermal stability (Maeda et al., 2014). This trend applies to all of the RP 
mutant pigments (as well as WT rhodopsin). G101V is very unstable at high temperatures but once 
repaired has similar stability to WT (Figure 3.15). Little is known about this mutation, with most 
studies stating that G101V is a class II mutation and causes an RP phenotype (Wan et al., 2019), so this 
characteristic is a potential new property. V104F is comparable to WT and is stable at high 
temperatures once repaired (Figure 3.16). Again, not much is known about this mutation, but studies 
have been conducted about a similar mutation, V104I (Valine to Isoleucine). V104I is classified as a 
benign mutation and does not result in an RP phenotype (phenotypically silent) (Macke et al., 1993, 
Wan et al., 2019). However, these results show that V104F might not be completely silent and may 
result in a mild RP phenotype as stability characteristics are similar (but slightly lower) than WT. When 
G106W is exposed to high temperatures, the protein falls apart with a very short half-life (Figure 3.17). 
This result also seems to form a trend as a similar mutation, G106R (Glycine to Arginine), is unstable 
and causes a severe RP phenotype (Fishman et al., 1992). Possible reasons for this RP mutant’s 
instability could be due to G106W interfering with the binding area for retinal (Tryptophan amino acid 
protruding into the cleft in between the transmembrane helices) or maybe due to the mutation 
affecting an essential disulphide bridge (Wan et al., 2019). The disulphide bridge between Cysteine 
110 and Cysteine 187 is conserved in vertebrates and if interfered with can result in a defective 
rhodopsin molecule and unusual “rod dark adaptation kinetics”, which can result in a greater amount 
of retinal damage from light in a shorter period of time (Bareil et al., 1999). From Figures 3.14 to 3.17, 
there appears to be a trend as the RP mutants in the N2C/D282C background have increased thermal 
stability half-lives when compared to the non-repaired RP mutants. G101V N2C/D282C mutant 
pigment has a half-life 22-fold greater than that of the G101V mutant pigment and V104F N2C/D282C 
& WT N2C/D282C mutant pigments have half-lives 2.5-fold greater than V104F and WT pigments 
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respectively. These trends agree with results found in previous studies (Xie et al., 2003; Opefi et al., 
2013) in the context that a disulphide bridge can increase the rhodopsin pigment thermal stability 
when a RP mutation is also present. For the thermal decay graphs (Figures 3.14 to 3.16, not 3.17) fixed 
endpoints were extrapolated from the non-repaired RP mutant (and WT) graphs. This is due to the 
length of time needed to reach completion. An alternative is to carry out a partial thermal decay 
followed by photobleaching the pigment sample to reach the end point. However, the 500 nm 
absorbance peak will not fully reach zero as there is always a retinal shoulder contribution.  
4.3 Dark state spectral properties of mutant pigments and their photoconversion to the active state 
(Metarhodopsin II) 
WT, V104F and their repaired counterparts show very similar spectral properties and photoconversion 
to the Meta-II active state (Results- Figure 3.11). It can also be noted that their expression levels 
(Results- Figures 3.6 & 3.7) and thermal stabilities (Results- Figures 3.14 & 3.16) are similar. However, 
G101V and G106W show somewhat unusual dark state spectral properties, partly due these samples 
being rescued, and excess 9-cis-retinal remaining within the sample solution after the purification 
process. Yet this over-saturation of retinal did not have any effect on the pigment’s photoconversion 
to the Meta-II state and only shows an increased peak at 360 nm of the dark spectra, as shown in 
Figure 3.11 for G101V and G106W (Jastrzebska et al., 2009). However the spectra for RP mutants 
G101V and G106W show some resistance to photobleaching, meaning that the mutant rhodopsin 
pigments have not been fully converted to the 440 nm species (Kaushal and Khorana, 1994; Krebs et 
al., 2010). This could be due to rapid photoconversion to the intermediate states (Meta-I and Meta-II 
rhodopsin) as well as the fast decay of the Meta-II state and release of all-trans retinal prior to 
pigment acidification (Resek et al., 1993; Opefi et al., 2013). The presence of the disulphide bridge did 
not hinder the repaired WT and V104F RP pigments activation in any way (Standfuss et al., 2008) and 
corrected the abnormal bleaching spectra for G101V and G106W. 
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4.4 Stability of the active state of RP mutants located in ECL 1 
WT and WT N2C/D282C show very similar active state stability characteristics in Figure 3.12 and are 
the most stable rhodopsin pigments in the active state. The RP mutants show a trend as the repaired 
protein variants are more stable in the active state and possess a longer half-life than their non-
repaired versions. V104F and G106W have similar active state stabilities to each other yet G101V has a 
significantly shorter half-life than the other two RP mutants. Repaired V104F and G106W have slightly 
longer half-lives but G101V N2C/D282C has a half-life twice as long as non-repaired G101V. Each 
rhodopsin pigment Meta-II decay functions (WT, RP mutants and RP mutant in N2C/D282C 
background) are single component. These results agree with those that have been found previously 
(Xie et al., 2003) and these RP mutants can perform the photoactivation cascade, but have accelerated 
levels of decay once in the active state (Resek et al., 1993; Heck et al., 2003) perhaps due to an 
interfered Cys110-Cys187 disulphide bridge (Aguilà et al., 2020; Woods and Pfeffer, 2020). A trend 
emerges as the half-lives for the repaired rhodopsin pigments are longer than those for their 
respective non-repaired counterparts, indicating that the presence of the N2C/D282C disulphide 
bridge improves Meta-II state rhodopsin stability (Figure 3.13) (Opefi et al., 2013).  
4.5 Use of PyMol to investigate the basic structural perturbations in these mutants 
Analysing the protein structure should give us a greater depth of knowledge into understanding how 
the mutant proteins behave. Using the amino acid sequence and the computer software program 
PyMol, we can visualise the changes that substituting one amino acid for another could have. Starting 
with the disulphide bridge (N2C/D282C in purple), we can see how replacing the Asparagine and 
Aspartic Acid residues with Cysteine drastically increases their proximity to each other and forms a 
disulphide bridge to anchor the amino tail to ECL 3 (represented by dashed lines in Figure 4.1). 
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Figure 4.1- Rhodopsin N2C/D282C protein structure. PyMol was used to create a three-dimensional rhodopsin protein 
structure showing both the non-mutated (top) and mutated (bottom) areas in purple with the purple lines representing the 
disulphide bridge. This disulphide bridge then allows the N-terminus to bind tightly to ECL 3 and increase structural stability. 
Blue regions are carbohydrates at glycosylation sites. N2C removes a glycosylation sites, therefore the carbohydrate is no 
longer attached. 
The same has been done with G101V, V104F and G106W, although there are several different 
orientations in which the mutated residues can take. Some of the orientations have fewer interactions 
than others, these are being deemed the ‘best’ positions and are used in Figure 4.2 below (all other 
positions are shown in the Appendix). In G101V, the Glycine residue is simple and does not have any 
protruding side branches that can interfere with other parts of the protein molecule. However, when 
this is replaced by Valine, there is likely to be interactions with residues 27 and 29. These interactions 
show that the mutated residue cannot exist in that location without causing issues for a different part 
of the protein. In Figure 4.2 G101V is shown in red along with its orbital of interactions, there are 
N2 
D282 
Asparagine 2 / 
Aspartic Acid 282 
N2C 
D282C 
Asparagine 2 Cysteine/ 
Aspartic Acid 282 Cysteine 
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many interactions due to the protruding branches of Valine. V104F (in green) has a larger orbital 
around Valine but when replaced with Phenylalanine there is an overwhelming number of interactions 
with surrounding amino acids such as residues 27, 102 and 105. But in a couple of positions 
Phenylalanine does not interfere with any other residues, however the mutated residue is sticking out 
of the molecule so may cause issues with protein translocation to the cell surface or when situated in 
the cell’s plasma membrane. G106W (in blue) is very similar to G101V as Glycine has no external 
branches that could interfere with other protein residues. But when substituted for Tryptophan, there 
are multiple interactions for each possible position, meaning there is no theoretical unhindered 
orientation. Most negative interactions seem to be with similar residues as stated before, as well as 
residues 24 and 107. The Tryptophan residues, no matter the position, always seems to stick into the 
protein molecule (and potentially the binding cleft for the retinal chromophore). Combining these 
PyMol observations with the fact that G101V and G106W are the least stable pigments, it is 
reasonable to presume that the residues somewhat protrude into the retinal binding cleft and 
interfere with rhodopsin pigment formation. This is backed up by their photobleaching properties and 
similar effects found in ECL 2 (which acts as a cap above the retinal binding cleft).  
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Figure 4.2- Mutant Rhodopsin protein structures. PyMol was used to create three-dimensional rhodopsin protein structures 
containing their normal amino acid sequence (images on the left) and the mutated amino acid residues (images on the right). 
Images contain the area in which the amino acid can have interactions and any negative interferences with other parts of the 
protein are highlighted by red circles and interacting residues labelled in white. All images on the right show the ‘best’ 
residue positions with the least amount of negative interactions. RP mutations highlighted by coloured arrows: G101 & 
G101V are red, V104 & V104F are green and G106 & G106W are blue.  
Combining these PyMol images with the other results, we can start see why G101V and G106W are 
much more unstable than V104F, but we can also understand why WT is superior to all of the mutants 
and how the N2C/D282C disulphide bridge can be formed by close proximity Cysteine residues.  
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4.6 Explanatory model for the role of ECL 1 in structure and pathology 
In terms of the three rhodopsin RP mutations we can conclude that (using these results and other 
investigations); G101V and G106W pigments, but not V104F pigment, are rescued by the introduction 
of retinal during the folding process and repaired in the N2C/D282C background. The most logical 
rationale behind these observations is that the presence of the G101V and G106W RP mutations 
prevent the N-terminal cap of rhodopsin from correctly docking with ECL 3 and engaging with the ECL 
1 loop, resulting in the destabilisation of the rhodopsin helical bundle (Opefi et al., 2013). However, if 
retinal is present during rhodopsin pigment folding then the helical bundle becomes stabilised upon 
retinal binding. On the other hand, mutated residue protrusions into the retinal binding pocket can 
weaken interactions between the rod opsin apoprotein and retinal ligand (Woods and Pfeffer, 2020). 
In the case of the N2C/D282C background RP mutants, if the N2C/D282C disulphide bridge forms 
during the folding of the rod opsin apoprotein, the N-terminal cap becomes more tightly associated 
with the ECL 1 loop (and therefore all of the other ECL loops) to stabilise rhodopsin’s helical structure 
(as ECL 1 coordinates the position of transmembrane helices 2 & 3) (Opefi et al., 2013). Although, 
these ECL 1 mutations may affect the Cys110-Cys187 disulphide bridge reducing stability, signal 
transmission and receptor dynamics (Woods and Pfeffer, 2020). We can assume that the extracellular 
regions of rhodopsin have essentially been free to evolve a compact structure with unique 
thermostability and activation of rhodopsin in dark conditions. From this, the N-terminal cap is integral 
but not completely necessary for the formation of the helical bundle (as pharmacological chaperone 
rescue by retinal can improve pigment stability) (Krebs et al., 2010). Instead, it is likely that the N-
terminal cap only adds to the overall stability of the rhodopsin pigment structure. Looking at 
disulphide bridge mediated repair, the N2C/D282C bond appears to restore pigment folding, 
indicating that the N-terminal cap stabilises the helical structure and maintains the correct shape of 
the ligand-binding site. The N2C/D282C bond also improves pigment thermal stability, improves Meta-
II decay kinetics and shows photobleaching characteristics similar to WT rhodopsin. This suggests that 
the N2C/D282C bridge binds the N-terminal cap to ECL 3 (and has interactions with ECL 1 & 2) and 
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improves stability and photoactivation but is not absolute (in the case of V104F, there is little 
difference between non-repaired and repaired pigment characteristics except for thermostability) 
(Opefi et al., 2013). Yet mutations in the ECLs can affect N-terminal cap function by reducing local 
interactions. This in turn can alter transmembrane helical orientation and reduce pigment stability 
(Ahuja et al., 2009).  
A comparison of both pharmacological chaperone rescue and disulphide bridge mediated repair 
highlights rhodopsin’s N-terminal cap as critical for maintaining stability and function, whilst the RP 
mutants present in ECL 1 hinder said structural stability. All of the mechanisms are displayed in Figure 
4.3.  
The Endoplasmic reticulum Associated protein Degradation system (ERAD) is a cellular pathway that 
targets misfolded proteins in the ER for destruction by the proteasomes (Groisman et al., 2006). The 
ERAD system begins by identifying misfolded proteins, possibly by hydrophobic protein regions being 
exposed or unprocessed glycans. If the misfolded proteins cannot be restored to their native 
conformation, then these proteins are translocated to the cytoplasm for polyubiquitination by E1, 2 
and 3 ligase enzymes. The ubiquitination allows the misfolded proteins to be recognised by the 19S 
proteasome caps, leading to the degradation of the proteins (Olzmann et al., 2013). In rod 
photoreceptor cells, calnexin is used to identify misfolded or mutated rhodopsin pigments 
(Kosmaoglou et al., 2009). However the process is more tightly regulated than in other mammalian 
cells as over-regulation can result in restorable pigment proteins (e.g. those that can be rescued by the 
binding of retinal) are degraded prematurely and under-regulation leads to misfolded protein 
aggregation and can inhibit proteasome function (Kosmaoglou et al., 2009). 
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Figure 4.3- Schematic illustration of pharmacological chaperone rescue and disulphide bridge mediated repair for adRP 
rhodopsin mutants. A) WT rod opsin apoprotein folds correctly in the Endoplasmic Reticulum (ER) before translocation to 
the cell surface and binding with retinal to form rhodopsin. B) adRP mutants fail to fold correctly and N-terminal cap does not 
bind to extracellular region, resulting in destabilised helical bundle structure and mutant apoprotein is destroyed by ER 
associated protein degradation (ERAD). C) Pharmacological chaperone rescue with 9-cis-retinal corrects folding of RP mutant 
and translocates to cell surface. Formed pigments still exhibit unstable properties. D) Disulphide bridge mediated repair fixes 
N-terminal cap in place, restoring correct protein folding and characteristics. RP mutations in ECL 1 indicated by red star. 
Adapted from Opefi et al., 2013.  
As the RP mutant pigments in this study are all less stable than WT rhodopsin, it is not out of the 
question to assume that they, at least, produce a moderate RP phenotype. Their relation to RP disease 
progression is especially insightful. The production of defective or misfolded proteins is a normal part 
of cellular metabolism, however a large accumulation of these RP pigments can lead to ER stress and 
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cell death (Rao and Bredesen, 2004). Some misfolded pigments may be able to evade the ER 
degradation systems and escape to the rod outer segments (ROS). The presence of said defective 
pigments in the ROS is serious as they can begin to aggregate together and lead to mechanical cell 
breakdown via the destabilisation of the rod cell membrane (Haeri and Knox, 2012). This may be due 
to the release of retinal following isomerisation from 11-cis to the all-trans state once photobleached. 
In individuals without RP, the retinal molecules would be replaced by non-isomerised versions 
naturally present, but in those affected by RP the mutant pigments may exhibit cytotoxic properties 
(Galy et al., 2005). G101V, V104F and G106W RP pigments have not been specifically tested to see 
their relevant retinal degeneration characteristics, but severe RP mutants have (for example P23H). 
However, in humans it has been observed that retinal degeneration is independent to light exposure 
(i.e. it still occurs in the dark) and RP progression tends to start in the lower retina as it is exposed to 
brighter amounts of light (Cideciyan et al., 1998; Tam and Moritz, 2007). It should also be noted that 
ECL 1 has been found to bind/influence ligands, alter transmembrane helical positioning and partially 
coordinate activation (Wheatley et al., 2012; Barwell et al., 2012). This could somewhat explain why 
some mutations (e.g. V104F) are unaffected by pharmacological chaperone rescue.  
The main limitations of this study are the number of repeats and time. This study conducted triplicate 
repeats of each experiment with each protein variant to gain concordant averages, and that can be 
deemed representative. However a greater number of repeats would be beneficial as more 
concordant results would give averages that are more representative of what happens in nature.  
Additional experiments that could be carried out to further this study include; Transducin Assays, 
Arrestin binding and alternative chromophores for chaperone rescue. A Transducin Assay can be used 
to analysis and investigate the rhodopsin protein’s activation pathway. This experiment will record the 
relative increase in Tryptophan fluorescence of transducin, when transducin binds to activated 
rhodopsin (Metarhodopsin II) in the presence of GTP. Mutant pigment results can be compared to a 
WT rhodopsin control to see how effective the activation pathway is. Previous studies have found that 
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some mutations are similar to WT activation levels (E134Q at 98% (Franke et al., 1992)) whereas 
others have drastically reduced activation levels (T234V at 40% and R153Q at 8%). Along with this, it 
has been identified that correct protein folding and Meta-II stability are needed for the signal 
transduction pathway to function properly (Ernst et al., 1995, Franke et al., 1992). In addition to this, 
the binding properties with arrestin could also be investigated. During the deactivation pathway, 
arrestin binds to activated rhodopsin in order to dephosphorylate and regenerate the protein (Okawa 
and Sampath, 2007). However, some RP mutants have been found to activate and remain bound to 
arrestin after 11-cis-retinal has dissociated. This results in rhodopsin being unable to dephosphorylate 
and therefore cannot regenerate (Bareil et al., 1999, Mendes et al., 2005). A third additional 
experiment is to replace 9-cis-retinal with a different chaperone molecule, 5,8-epxoy-13-cis retinoic 
acid (13-cis-5,8-ERA). 13-cis-5,8-ERA was virtually screened and discovered to fit the retinal binding 
pocket relatively well, as well as having a high structural similarity to 11-cis-retinal (Ortega and 
Jastrzebska, 2019). This chaperone has been found to mitigate ER retention whilst also promoting 
plasma membrane localisation, and has worked well with T17M, P23H and E181K (inserted Lysine 
creates another salt bridge and increases chaperone-protein stability) (Behnen et al., 2018). Cellular 
localisation of the mutant proteins could also be looked at by adding a Green Fluorescent Protein 
(GFP) sequence to the mutant DNA and observe where the expressed protein tends to accumulate 
within the cell via fluorescent microscopy (Saliba et al., 2002, Sung et al., 1991).  
Future studies could be based upon this one but investigate other mutations on different residues 
located within ECL 1 such as Y102, F103 and F105 or look at different mutations to the residues used 
in this study, V104K for example. Alternatively, a future study could look at other class II mutations in 
different parts of the rhodopsin protein. Both of these can then be compared with this study to see if 
mutations in the same region or mutations of the same class have similar characteristics, stability 
issues and resulting RP phenotypes. A third future study could revolve around the RP mutant pigment 
structures, and how the inserted mutations affect the entire protein. This would involve (energy) 
minimisation, a computational technique used to determine the orientation of atoms, molecules or 
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ions based on their minimum energy states, according to an algorithm (Jensen, 2017). The process 
would require the proteins to be solvated (generally in water) and neutralised (e.g. with sodium ions) 
before being minimised by the steepest decent method to remove amino acid residue clashes. The 
minimised protein sequences can then be visualised using PyMol. In simplistic terms, this method is 
used to show which position(s) the amino acid residues are most likely to exist in. Root mean square 
deviations can also be used to prove these. Software packages such as GROMACS or Amber 9 can be 
used for this (Ge et al., 2012; Qadah and Jamal, 2019). Ultimately, all of these additional and future 
studies have one common goal, to better our knowledge about RP and its developmental 
mechanism(s) and one day result in a treatment that may not cure the disease, but at least slow down 
the progression of blindness to give the individual a few more years of sight and normality.   
In conclusion, this study can say that the presence of an additional disulphide bridge between inserted 
Cysteines at residues 2 and 282 increases the thermal stability of rhodopsin and that the 
pharmacological chaperone 9-cis-retinal can help rescue misfolded proteins and increase mutant RP 
pigment expression. In regards to the mutations of this study, G101V and G106W are both thermally 
unstable yet have good Meta-II stability levels. Whilst V104F has both good thermal stability and 
Meta-II stability, but all mutants have lower stability and activation levels when compared to WT 
rhodopsin. The main contributions are the characteristics identified for G101V and V104F as they, at 
most, have only been mentioned or their properties theorised in other studies but have not been 
investigated. This study agrees with the hypothesis that the presence of the ECL 1 RP mutations cause 
the N-terminal cap to fail to associate productively with the docking region in ECL 3. This in turn 
results in a destabilised rhodopsin pigment with reduced expression levels, thermal instability, altered 
photobleaching properties and reduced active state kinetics. However more research is needed on the 
mutations in this study, as well as other mutants that are not yet characterised, in order to understand 
in greater depth the mechanism(s) of rhodopsin malfunction in Retinitis Pigmentosa (Wan et al., 
2019).  
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6. Appendices 
6.1 Rhodopsin sequence homology 
Using the Emboss needle website, sequence alignments for bovine rhodopsin pigment (top sequence) 
and human rhodopsin sequence (bottom sequence) have a similarity of 97.4%, with only 19 amino 
acids being different between the two. Due to the high sequence similarity, bovine rhodopsin is used 
instead of human rhodopsin as it is easier to crystallise and experiment on. The black arrow indicate 
the amino acid at residue number two (N2), the yellow, red and green arrows highlight the amino acid 
residues at 101, 104 and 106 respectively (G101, V104 and G106W). Finally the blue arrow indicates 
the amino acid residue at number 282 (D for bovine rhodopsin and N for human rhodopsin).  These 
are the amino acid residues involved in this project. Based on Kanwal et al., 2012. 
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6.2 MidiPrep yield and UV absorbance properties of purified samples 
MidiPrep DNA concentrations and purity data recorded from Nanodrop 1000 Spectrophotometer for 
each mutant DNA sample produce by MidiPrep (this data is the first set of MidiPreps completed, these 
were repeated when necessary to ensure sufficient amounts of DNA were prepared). Glycerol stocks 
were used along with ampicillin growth plates. 
Mutant Sample DNA Concertation 
(ng/µl) 
260/280 
Value 
260/230 
Value 
WT 1098.7 1.91 2.32 
WT N2C/D282C 1411 1.91 2.32 
G101V 1851.1 1.90 2.31 
G101V N2C/D282C 1127.3 1.90 2.30 
V104F 437 1.87 2.28 
V104F N2C/D282C 212.9 1.92 2.27 
G106W 621 1.90 2.28 
G106W N2C/D282C 651.6 1.91 2.19 
pRSV T-ag 862 NA NA 
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6.3 Rhodopsin pigment expression levels using disulphide bridge mediated repair or 
pharmacological chaperone rescue with 9-cis-retinal 
Amount of protein produced by each RP mutant and RP mutant in N2C/D282C background, with a wild 
type control. The protein production levels have been based upon the difference between normalised 
dark and light UV-visible spectrophotometer absorbance values, and then adjusted to coincide with 
the 0.55 ml sample volume.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutant Run 1 Run 2 Run 3 Averages 
WT 1 17.6 25.3 25.9 22.9 
WT 2 14.3 28.6 27.0 23.3 
WT 3 - 30.8 29.7 30.3 
G101V 1 2.2 5.5 3.9 3.9 
G101V 2 5.0 5.5 3.9 4.8 
G101V 3 2.8 0.6 5.0 2.8 
G101V N2C/D282C 1 5.0 9.4 8.3 7.5 
G101V N2C/D282C 2 3.9 11.6 10.5 8.6 
G101V N2C/D282C 3 - 10.5 11.0 10.7 
WT 1 16.5 15.4 21.5 17.8 
WT 2 13.8 22.6 20.9 19.1 
WT 3 22.0 - 16.5 19.3 
V104F 1 17.1 16.5 20.9 18.2 
V104F 2 12.7 18.2 17.1 16.0 
V104F 3 9.4 14.9 15.4 13.2 
V104F N2C/D282C 1 15.4 15.4 16.5 15.8 
V104F N2C/D282C 2 12.7 12.1 12.7 12.5 
V104F N2C/D282C 3 12.1 16.0 15.4 14.5 
WT 1 23.1 27.5  25.5 26.2 
WT 2 21.5 16.5  21 20.4 
WT 3 - 29.2  20 25.6 
G106W 1 0.6 2.2  1.5 1.5 
G106W 2 1.1 0.6  1.5 1.1 
G106W 3 - 2.8  1.0 1.9 
G106W N2C/D282C 1 4.4 12.7  13.5 10.6 
G106W N2C/D282C 2 6.1 6.1  10 7.7 
G106W N2C/D282C 3 6.6 8.3  8.5 8.1 
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Amount of protein produced by each RP mutant and RP mutant in N2C/D282C background that have 
been rescued using 9-cis-retinal during transfection, with a wild type control. The protein production 
levels have been based upon the difference between normalised dark and light UV-visible 
spectrophotometer absorbance values, and then adjusted to coincide with the 0.55ml sample volume.  
Mutant (Rescued) Run 1 Run 2 Run 3 Averages 
WT 1 10.5 - - 10.5 
WT 2 11.0 - - 11.0 
WT 3 9.9 - - 9.9 
G101V 1 6.1 5.0 6.6 5.9 
G101V 2 5.5 6.1 6.1 5.9 
G101V 3 5.0 7.2 6.1 6.1 
G101V N2C/D282C 1 5.5 6.1 5.0 5.5 
G101V N2C/D282C 2 5.0 5.5 2.2 4.2 
G101V N2C/D282C 3  5.5 6.1 7.2 6.2 
WT 1 12.7 - - 12.7 
WT 2 12.1 - - 12.1 
WT 3 14.9 - - 14.9 
V104F 1 13.2 7.7 9.4 10.1 
V104F 2 12.1 8.3 7.7 9.4 
V104F 3 14.9 8.3 6.6 9.9 
V104F N2C/D282C 1 6.6 8.3 8.3 7.7 
V104F N2C/D282C 2 16.0 7.2 12.7 11.9 
V104F N2C/D282C 3 
 
7.7 2.8 5.2 
WT 1 9.4 -  - 9.4 
WT 2 9.9 -  - 9.9 
WT 3 7.7 -  - 7.7 
G106W 1 5.5 7.2 5.0  5.9 
G106W 2 6.1 5.0 5.0 5.3 
G106W 3 5.5 4.4  5.5 5.1 
G106W N2C/D282C 1 8.8 7.7  8.8 8.4 
G106W N2C/D282C 2 6.1 6.1  8.8 7.0 
G106W N2C/D282C 3 7.7 6.6  8.8 7.7 
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6.4 ANOVA Statistics 
ANOVA test of the disulphide bridge repaired rhodopsin RP mutants (Table 6.1), rescued rhodopsin RP 
mutants (Table 6.2) and rescued-repaired rhodopsin RP mutants (Table 6.3). Statistical ANOVA test 
carried out to compare the variance both between and within each group to determine whether said 
groups are significantly different from each other or not. This was then compared with an α-value of 
0.05 to give both a p-value and f-critical value.  
Table 6.1- Disulphide bridge repaired rhodopsin RP mutant statistics (RP vs. RP N2C/D282C) 
SUMMARY        
Groups Count Sum Average  Variance   
WT 9 204.20 22.69  16.67   
WT N2C/D282C 3 38.60 12.87  31.76   
G101V 9 34.10 3.79  2.83   
G101V N2C/D282C 8 69.85 8.73  8.25   
V104F 9 141.90 15.77  10.97   
V104F N2C/D282C 9 128.15 14.24  3.29   
G106W 8 11.55 1.44  0.60   
G106W N2C/D282C 9 79.20 8.80  12.02   
        
        
ANOVA        
Source of Variation SS df MS  F P-value F crit 
Between Groups 2822.15 7 403.16  45.92 6.18E-21 2.18 
Within Groups 491.65 56 8.78     
        
Total 3313.80 63          
 
It is clear that the p-value is well below 0.05 and the variance between and within the mutant sample 
groups strongly suggests that these groups are significantly different (F7,56= 45.92, P<0.05). From this 
we can see that there is a large variance between mutant sample groups when looking at the effect of 
disulphide bridge repair, and when compared with the spectroscopy data (Results- Figure 3.6) this is 
the case.  
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Table 6.2- Pharmacological chaperone rescued rhodopsin RP mutant statistics (RP vs. RP rescued) 
 
SUMMARY       
Groups Count Sum Average Variance   
WT 9 204.20 22.69 16.67   
WT rescued 9 97.90 10.88 4.37   
G101V  9 34.10 3.79 2.83   
G101V rescued 9 53.35 5.93 0.51   
V104F  9 141.90 15.77 10.97   
V104F rescued 9 88.00 9.78 8.30   
G106W 8 11.55 1.44 0.59   
G106W rescued 9 48.95 5.44 0.64   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Between Groups 3012.38 7 430.34 75.63 3.21E-28 2.16 
Within Groups 358.49 63 5.69    
       
Total 3370.86 70         
 
Similar to above, shows a p-value well below 0.05. The variance between and within the rescued 
mutant sample groups indicates that said groups are significantly different (F7,63= 75.63, p<0.05) than 
those in Table 6.3. This is also visible in Results- Figure 3.6, as the average amount of protein produced 
by each rescued sample falls within a range of about 5 µg from most produced (WT at 11 µg) and least 
produced (G101V N2C/D282C or G106W at 7 µg).  
 
 
 
 
 
 
 
 
Table 6.3- Rescued-repaired rhodopsin RP mutant statistics (RP N2C/D282C vs. rescued RP N2C/D282C) 
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This test indicates that the mutant samples are more significantly similar than those show in the other 
tables above (F7,56= 9.60, p<0.05). 
Overall, we can see that pharmacological chaperone rescue seems to have had some influence on the 
amount of rhodopsin produced by the samples that do not contain the N2C/D282C mutation. V104F 
does not seem to have responded to the presence of 9-cis-retinal, but there is not a significant 
difference between V104F and V104F N2C/D282C anyway. On the other hand, G101V and G106W 
have responded to the addition of 9-cis-retinal. The rescued G101V and G106W mutant samples have 
produced a similar amount of rhodopsin as their repaired mutant versions, and significantly more than 
the non-rescued and non-repaired G101V and G106W mutants. The difference between the rescued 
and non-rescued samples being approximately 2 µg for G101V and 6 µg for G106W.  
 
 
SUMMARY       
Groups Count Sum Average Variance   
WT N2C/D282C 3 38.60 12.87 31.76   
WT N2C/D282C Rescued 9 64.25 7.139 0.29   
G101V N2C/D282C 8 69.85 8.73 8.25   
G101V N2C/D282C Rescued 9 47.85 5.32 1.82   
V104F N2C/D282C 9 128.15 14.24 3.29   
V104F N2C/D282C Rescued 8 69.30 8.66 15.97   
G106W N2C/D282C 9 79.20 8.80 12.02   
G106W N2C/D282C Rescued 9 69.30 7.70 1.44   
       
       
ANOVA       
Source of Variation SS df MS F P-value F crit 
Between Groups 460.79 7 65.83 9.60 8.82E-08 2.18 
Within Groups 383.89 56 6.86    
       
Total 844.69 63         
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6.5 PyMol RP rhodopsin structure perturbations 
Rhodopsin structural changes observed using PyMol software to visualise amino acid substitutions for 
the disulphide bridge (N2C/D282C), G101V, V104F and G106W. Potential amino acid orientations are 
shown with their appropriate orbitals of interactions (red circles indicate negative interactions with 
other amino acid residues within the rhodopsin molecule). Best positions, those with the fewest 
negative interactions, are shown in the Discussion. White arrows show labelled residues with which 
negative interactions occur. 
WT N2C/D282C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT N2C/D282C 
Asparagine 2 / Aspartic Acid 282 
(WT) 
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Mutated G101V orientations 
 
Mutated V104F orientations 
 
 
 
 
 
 
 
 
94 
 
Mutated G106W orientations 
 
 
 
 
